

Synthesis and Functionalization of C6/C7 Substituted Pyrido[3,2-*d*]pyrimidines

Philipp E. Hofmann⁺,^[a] Jannick Meinecke⁺,^[a] Klaus Harms,^[a] and Ulrich Koert^{*[a]}

Dedicated to the memory of Prof. Dr. Klaus Hafner.

An efficient synthesis of functionalized pyrido[3,2-d]pyrimidines is reported. Starting from 4-aminopyrimidine-3-carbaldehydes, a Horner-Wadsworth-Emmons olefination followed by a photoisomerization/cyclization installed the fused pyridine ring. Using substituted HWE-reagents various substituents could be intro-

Introduction

Pyridopyrimidines are heteroaromatic scaffolds of interest for life-science applications in particular medicinal chemistry.^[1] Among them pyrido[3,2-*d*]pyrimidines play a prominent role. Selected recent examples for their use in the development of drug type compounds include: toll-like receptor 8 agonist selgantolimod,^[2] dual PI3 K/mTor inhibitor cmG002,^[3] kinase ERK5 probe BAY-885,^[4] PI3Kd-inhibitor seletalisib,^[5] and p38a MAP-kinase inhibitor R1487.^[6] Furthermore, pyrido[3,2-*d*] pyrimidines are promising building blocks for functional materials e.g. organic nanotubes.^[7]

The chemistry of pyridopyrimidines and synthetic access to various substitution patterns for this heteroaromatic system are an active field of organic synthesis.^[8]

Synthetic routes to substituted pyrido[3,2-*d*]pyrimidines 1 can be divided into three approaches (Scheme 1).^[8] The first route A uses intermediates of type 2 which can be prepared starting from a substituted pyridine for example by condensation of carbon dioxide with an 3-amino-2-cyano-pyridine **3**.^[9] The second route B uses sequential chemoselective substitution reactions of commercially available di- and trichloropyridopyrimidines **4**. This approach was mainly developed by the Orleans group of Guillaumet and Routier.^[10]

The third approach C utilizes intermediates of type **5** which could be prepared from a substituted pyrimidine for example by an olefination reaction of an 4-aminopyrimidine-3-carboxaldehyde **6** with a Wittig-type reagent **7** followed by pyridone



[⁺] Autors contributed equally.

Supporting information for this article is available on the WWW under https://doi.org/10.1002/ejoc.202100593

Part of the "Special Collection in Memory of Klaus Hafner".

© 2021 The Authors. European Journal of Organic Chemistry published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. duced in the 7-position of the pyrido[3,2-*d*]pyrimidines. Functionalization of the pyridone substructure allowed late variation in the 6-position. In order to obtain amine-linked bis-pyridopyrimidines, 7-bromo-pyridopyrimidines were converted with their 7-amino-counterpart by Hartwig–Buchwald amination.



Scheme 1. Three synthetic routes to substituted pyrido[3,2-d]pyrimidines 1 and structures of bis-pyrido[3,2-d]pyrimidines 8 and polyazapentacene 9.

ring closure. This route is less developed.^[11] We intended to apply bis-pyrido[3,2-*d*]pyrimidines **8** for the synthesis of polyazapentacene **9** with interesting semiconductor properties.^[12] Here we report the use of the third synthetic route C as an



efficient access to substituted pyrido[3,2-*d*]pyrimidines such as **5** and to dimers of type **8**.

Results and Discussion

Starting point for the synthesis of the aminopyrimidine carbaldehyde moiety 6 was the bromo-pyrimidine carboxylic acid 11 (Scheme 2). With catalytic amounts of copper(II) sulfate in ammonia at 95 °C amination was achieved.^[13] Subsequent esterification to methyl ester 12 succeeded with diazomethane. In comparison to esterification with HBTU, DMAP in methanol (2 d, 65°C, 74%) and an existing protocol ^[14] shorter reaction times and higher yield were obtained with diazomethane. Optional desulfurization of thioether 12 was adapted from a procedure of Graham^[15] and gave pyrimidine 13. Which was then reduced under Luche conditions to the corresponding alcohol in 85%, whereas reduction of ester 12 to the corresponding alcohol proceeded best with DIBAH. Finally both alcohols underwent oxidation in a convenient manner with manganese dioxide^[14] to furnish respective aldehydes **14** in five steps (49%) and 15 in four steps (63%).



Scheme 2. Synthesis of aminopyrimidine carbaldehydes 14 and 15.



Scheme 3. HWE-reaction of aldehyde 14 resulted in *Z*-olefin 17-(*Z*) which underwent isomerization and condensation to pyridopyrimidine 18a.

Eur. J. Org. Chem. 2021, 1-20

Having the 5-aminopyrimidine carbaldehyde 14 in hand, we investigated its olefination reaction. While ethyl nitroacetate failed to deliver the desired Knoevenagel product, Horner-Wadsworth-Emmons (HWE) reaction with phosphonate $16^{(16)}$ resulted in 83% of the Z-olefin 17-(Z) (Scheme 3). With an isomerization of the obtained Z-olefin to the corresponding *E*-olefin the condensation reaction should be enabled. Earlier work from Horaguchi demonstrated that *E-ortho*-aminocinna-moyl derivatives underwent a light-induced isomerization (400 W high-pressure mercury lamp with Pyrex filter) in advance to intramolecular amidation to 2-quinolones.^[17] Guided by this we found optimal conditions for the isomerization in the pyrimidine case (LED 435 nm, MeOH, 60 °C) of the Z-isomer 17-(*Z*) to *E*-isomer 17-(*E*) and its subsequent spontaneous intramolecular condensation to the pyrido[3,2-*d*]pyrimidine-core 18.

The scope of the HWE reaction of aldehydes **14/15** with different phosphonates **16** to alkenes **17** and their subsequent photoisomerization/cyclization to pyrido[3,2-*d*]pyrimidines **18** is summarized in Scheme 4. By modifying the HWE-reaction pendants we were able to aim for various substitution patterns in 6,7-position of the resulting pyridopyrimidines.

The utilization of a Still-Gennari phosphonate 16a^[18] provided 17 a-(Z) with traces of 17 a-(E) while no direct cyclization to the pyridinone was observed, product 18a was obtained in the subsequent step. Introduction of an amine moiety succeeded with commercially available phosphonate 16b in excellent yield. Herein, the condensation product 18b was already obtained during olefination to 17b, which led us to the conclusion of receiving a 1:17 E/Z ratio. In an attempt to obtain a 2-picolin motif $(14+16 c/d \rightarrow 18c)$ with β -ketophosphonates^[19] we were able to isolate a mixture of the noncyclized E-olefin 17c and its analogue Z-olefin. A significant improvement of solubility and yield was obtained with a thioether incorporated in 2-position of the pyrimidine (15+ 16b-18d). Commercially available chloro-functionalized phosphonate 16e expanded the scope of applicable HWE-pendants and gave pyridopyrimidine 18e in 99% over two steps. Using the bromo-substituted HWE-reagent 16f the pyridone 18f was accessible. The β -ketophosphonates **16 c/d** led to the picolinopyrimidine 18 g.

With different substituents implemented in the 7-position by usage of the respective phosphonate, we addressed the conversion of pyridone-motifs in 6-position next. Three types of reactions were chosen for examination: deoxyhalogenation, sulfonate formation, and PyBroP mediated S_NAr reaction (Scheme 5). Triflation of the amide proceeded in moderate yield unaffected of the thioether presence (19a, 19e). Neat deoxyhalogenation towards chloride 19b as well as bromide 19c was achieved with neat POCl₃ and POBr₃, respectively. Subsequent fluorination of chloride 19g with TBAF resulted in fluoride 20a (41%) and pyridone 18e (57%) as major side product through hydrolysis. Deoxychlorination of pyridopyrimidine 18f (Y = Br) exhibited excellent NMR-yield but resulted in an inseparable mixture of the product and a side product which originated from nucleophilic aromatic substitution of the halide in 7position (not shown). Tosylation of carbamate-containing pyridopyrimidine (18b-19d) proceeded with selective O-

These are not the final page numbers! 77

www.eurioc.ora

2

Full Papers doi.org/10.1002/ejoc.202100593





Scheme 4. Scope of the HWE-reaction/photoisomerization/cyclization sequence to produce various pyrido[3,2-*d*]pyrimidines 18. All phosphonates except for carbamate-functionalized phosphonate 16 b (conditions b)), were treated with conditions a).

sulfonation in 82% proved by x-ray (see SI). The best result for this type of conversion was obtained by mesylation to sulfonate **19f** in excellent yield.



Scheme 5. Functionalization in C6-position of pyridopyrimidones 18 via deoxyhalogenation, sulfonation, or PyBrop mediated S_NAr .

A direct approach for the introduction of *N*-nucleophiles was realised with the *in situ* generation of a phosphonium leaving group induced by PyBroP.^[20] Nucleophilic substitution of **18f** and **18e** provided the 6-amino-pyridopyrimidines **19h**, **19i**, and **19j**. The latter could be debenzylated to **20b**. With (BnO)NH(Boc) the pyridopyrimidine **19k** was produced which could be Boc-deprotected to the hydroxylamine derivative **20c**.

A feasible connection to amino-bridged bis-pyridopyrimidines was primed with the free amine 20 b, which was synthesized by S_NAr with strong nucleophilic, easily soluble and acid labile benzylamine derivative $(18 e \rightarrow 19 j \rightarrow 20 b)$.

Scheme 6 displays viability of the 7-position for palladiumcatalyzed Hartwig–Buchwald coupling reactions.

Mono aminated pyridopyrimidine **19j** gave under strongly basic conditions diamino compound **21** in reasonable yield. Conversion of the aryl-bromide **18f** to amine **22** could be achieved, too. Apparently, no further conversion from secondary amine **22** to an amine bridged bis-pyridopyrimidine occurred. The pyridopyrimidine **18c**, which was synthesized





Scheme 6. Hartwig–Buchwald coupling enabled amination in 7-position.

from β -keto-phosphonate **16c/16d**, also underwent Hartwig– Buchwald coupling to yield amine **23** in very good yield.

On the way to bis-pyridopyrimidines we came across a sample of miscellaneous reactions to pyridopyrimidines **24–26** (Scheme 7). Benzylic oxidation of **18g** with selenium dioxide gave the corresponding aldehyde **24** in reasonable yield.



Scheme 7. Miscellaneous reactions to valuable building blocks 24-26.

Attempted S_NAr for **19g** with a Reformatski reagent gave surprisingly full conversion to compound **25**. One could anticipate Lewis-acid activation on the pyridine nitrogen through the reagent itself with subsequent vinylogous attack in C8-position. Attempts to introduce this moiety with palladium catalysis led to the same observation.

In order to decrease electron density in dichloride **19g** the thioether was oxidized to sulfone **26**.

A primary amino group in the 7 position should be less sterically hindered and therefore exhibits a promising building block for the synthesis of amino-bridged bis-pyridopyrimidines. Towards this end the *N*-Boc group in pyridopyrimidines **18b/d** were cleaved to deliver the primary amines as TFA salts **27 a/b** (Scheme 8). Palladium catalyzed coupling with the respective aryl bromides **18 c/18 g** gave bis-pyridopyrimidines **28 a** and **28 b**. An X-ray structure of compound **28 a** proved unequivocally the structural assignment. The thiomethyl ether group in **28 b** increased the solubility and allowed follow up chemistry. *N*-Boc protection of **28 b** gave carbamate **29**, which could be converted into various sulfonates **30**.

Due to the modular, mild and chemoselective conversion, the synthetic progress in the pyrido[3,2-*d*]pyrimidine area reported here, displays a valuable addition to the harsh condensation mediated pyrimidine ring synthesis (according to route A, Scheme 1) as default method in medicinal chemistry.^[2-5] In contrast to present aldol condensations of 5aminopyrimidine carbaldehydes to symmetrical ketones, the synthesis of the pyridine herein was enclosed in a regioselective manner and should therefore allow tailored design of novel pharmacophores or functional materials. The demonstrated follow-up conversions can help medicinal and material chemists to get a better understanding of reactivity and selectivity of 6,7substituted pyrido[3,2-*d*]pyrimidines. Therefore the utilization of pyrido[3,2-*d*]pyrimidines in these fields can be expanded.

Substituted pyrido[3,2-d]pyrimidines are accessible by a reac-

tion sequence consisting of HWE-reaction, a Z/E-photoisomeri-

zation, and ring closure of the pyridine ring. Substituents in the

Conclusion

18c (R = H) or 18g (R = SMe) Pd₂(dba)₃ XantPhos NHBoc NH₂TFA TFA Cs₂CO₃ CHCI N 1.4-dioxane 0 °C to rt 105 °C 27a, R = H (95%) 18b R = H 28a, R = H (74%) 27b, R = SMe (99%) 18d. R = SMe 28b, R = SMe (99%) Boc LGCI. DIPEA Boc MeS DMAP. THE Boc₂O 0°C DMAP. NEt ò THF, 4 A MS N 0 °C to rt 30a, LG = Tos (95%) 29 R = SMe (91%) 30b, LG = Nos(76%) **30c**, LG = Tf (68%)

Scheme 8. Access to bis-pyridopyrimidines was enabled by Hartwig-Buchwald coupling of amines 27 with the respective aryl bromide.

Eur. J. Org. Chem. **2021**, 1–20 ww

www.eurioc.ora

These are not the final page numbers! 77

© 2021 The Authors. European Journal of Organic Chemistry published



7-position can be brought in by substituted HWE-reagents, while substituents in the 6-position are accessible by late stage functionalization of the pyridine substructure. Bis-pyridopyrimidines can be obtained from 7-amino-pyrido[3,2-*d*]pyrimidines.

Experimental Section

Crystallographic data. CCDC 2081819–2081824 contain supplementary crystallographic data for 17b, 17d, 19d, 19j, 18e & 28a.

General Information. All anhydrous reactions were carried out using flame-dried glassware under argon atmosphere. All solvents were distilled by rotary evaporation. THF for anhydrous reactions was dried with KOH and subsequently distilled from sodium/ benzophenone and from Solvona® respectively. All other solvents employed under anhydrous and/or anaerobic conditions were bought in anhydrous form. All commercially available reagents and reactants were used without further purification unless otherwise noted. Reactions were monitored by thin layer chromatography (TLC) using MERCK Silica Gel 60 F254 and visualized by fluorescence quenching under UV-light. In addition, TLC-plates were stained using a cerium sulfate/phosphomolybdic acid stain or a potassium permanganate stain. Chromatographic purification of products was performed on MACHEREY-NAGEL Silica Gel 60 (230-400 mesh) using a forced flow of eluents. All crude products were adsorbed onto silica by dissolving in an appropriate solvent and removing the solvent under reduced pressure. Concentration under reduced pressure was performed by rotary evaporation at 40°C and appropriate pressure and by exposing to high vacuum at room temperature if necessary.

NMR-Spectroscopy. NMR-spectra were recorded on a BRUKER AVIII HD250, AVII 300, AVIII HD300, AVIII 500 or AVIII HD500 spectrometer at room temperature unless otherwise mentioned. Chemical shifts are reported in ppm with the solvent resonance as internal standard. All reported ¹⁹F-NMR spectra are proton decoupled ¹⁹F {¹H}-measurements and referenced to external CFCI₃. Data are reported as follows: s=singlet, d=doublet, t=triplet, q=quartet, quin=quintet, m=multiplet and combination thereof. All correlations of atoms from NMR spectra of new compounds could be achieved via additional 2D-NMR data (HSQC- and HMBC-spectra) which is not shown within these SI. All ¹³C{¹⁹F} spectra were recorded on AVIII 500 equipped with a 5 mm BBO (broadband observation) Cryo probe Prodigy.

High Resolution Mass Spectrometry. HR-ESI and APCI mass spectra were acquired with a Finnigan LTQ-FT Ultra mass spectrometer (THERMO FISCHER SCIENTIFIC). EI mass spectra were acquired with an AccuTOF GCv (JEOL) mass spectrometer.

Infrared Spectroscopy. FT-IR spectra were recorded on a BRUKER IFS 200 spectrometer. Intensities are reported as follows: s = strong, m = medium, w = weak.

Melting Points. Melting points were determined on a MP70 (METTLER TOLEDO) using one end closed capillary tubes.

Methyl 5-amino-2-(methylthio)pyrimidine-4-carboxylate (12)



Following a modified patent procedure^[13] in a pressure vessel carboxylic acid **11** (5.00 g, 20.1 mmol, 1.00 eq) and CuSO₄ (150 mg,

602 µmol, 0.03 eq) were dissolved in concentrated ammonia solution (32.0 mL) and heated to 95 °C for 5.5 h during which the pressure increased to 5 bar. The warm reaction mixture was filtered over a pad of celite and activated carbon and rinsed with water (10 mL). The filtrate was cooled to 0°C and the pH was adjusted to 3 with aqueous HCl (2 M, approx. 250 mL). At a pH value of 7 a yellow solid started to precipitate which reached a greater extent until pH value of 3. The precipitate was filtered and washed with aqueous HCI (0.001 M, 10 mL) and n-pentane (10 mL). After evaporation of the residual solvents in fine vacuum the amine was obtained as vellow solid (3.36 g, 18.1 mmol, 90%). $R_f = 0.70$ (EtOAc/ MeOH 1:1; 1% AcOH was added). ¹H-NMR (500 MHz, DMSO-d6): $\delta = 8.68$ (s(br), 2H, NH₂), 8.44 (s, 1H, CH_{arom}), 2.47 (s, 3H, SCH₃) ppm. $^{13}\text{C-NMR}$ (126 MHz, DMSO-d6): $\delta\!=\!$ 167.7 (1 C, COOH), 154.8 (1 C, C_{arom}SCH₃), 150.3 (1 C, CH_{arom}), 140.7 (1 C, C_{arom}), 131.5 (1 C, C_{arom}), 13.6 (1 C, SCH₃) ppm. FT-IR: neat; $\tilde{v} = 3450$ (w), 3288 (w), 3156 (w), 2933 (w), 2737 (w), 2622 (w), 2199 (w), 2179 (w), 2139 (w), 2034 (w), 2005 (w), 1965 (w), 1932 (w), 1905 (w), 1674 (s), 1614 (m), 1570 (m), 1537 (w), 1447 (w), 1414 (s), 1338 (w), 1321 (w), 1298 (w), 1230 (s), 1134 (m), 1048 (w), 961 (w), 933 (w), 891 (m), 792 (w), 739 (m), 723 (w), 702 (s) cm⁻¹. m.p.: 193 °C (MeOH). HRMS (ESI⁺): *m/z* calc. for $C_6H_7N_3O_2S_1Na_1$ [M + Na]⁺: 208.0151, found: 208.0151. The obtained compound (926 mg, 5.00 mmol, 1.00 eq) was then dissolved in THF (12.0 mL) and cooled to 0 °C. An ethereal solution of freshly distilled $CH_{2}N_{2}$ (approx. 20 mL, 5.00 mmol, 1.00 eq), which was prepared following literature procedure, was added dropwise.^[21] After stirring for 15 min the reaction mixture was allowed to warm to rt and stirred for additional 15 min before glacial acetic acid (3.0 mL) was added slowly. The reaction mixture was poured into saturated aqueous NaHCO₃ solution (50 mL) and extracted with EtOAc (3 \times 100 mL). The combined organic layers were washed with brine (50 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure to obtain compound 12 (997 mg, 5.00 mol, 99%) as yellow solid. R_f=0.24 (n-pentane/EtOAc 2:1). ¹H-NMR (300 MHz, DMSO-d6): δ = 8.47 (s, 1H, CH_{arom}), 6.54 (s, 2H, NH₂), 3.85 (s, 3H, OCH₃), 2.46 (s, 3H, SCH₃) ppm. ¹³C-NMR (75.5 MHz, DMSO-d6): δ = 166.2 (1 C, COOCH₃), 154.9 (1 C, C_{arom}), 150.5 (1 C, CH_{arom}), 140.5 (1 C, C_{arom}), 130.6 (1 C, C_{arom}), 52.1 (1 C, OCH₃), 13.5 (1 C, SCH₃) ppm. FT-IR: neat; \tilde{v} = 3439 (m), 3283 (m), 3200 (m), 3157 (m), 2992 (w), 2947 (m), 2928 (w), 3851 (w), 2198 (w), 2085 (w), 1998 (w), 1927 (w), 1693 (s), 1609 (s), 1568 (m), 1533 (m), 1442 (s), 1413 (s), 1389 (m), 1346 (m), 1323 (m), 1291 (m), 1222 (s), 1152 (m), 1121 (s), 1048 (m), 971 (m), 931 (m), 885 (m), 814 (m), 738 (s), 709 (s), 662 (s), 562 (w), 465 (m), 432 (m) cm⁻¹. m.p.: 124 °C (EtOAc). HRMS (ESI⁺): *m/z* calc. for $C_7H_9N_3O_2S_1Na_1$ [M + Na]⁺: 222.0308, found: 222.0308.

Methyl 5-aminopyrimidine-4-carboxylate (13)



Methylthiopyrimidine **12** (600 mg, 3.01 mmol, 1.00 eq) and Pd/C (10 wt%, 96.1 mg, 90.0 µmol, 0.03 eq) were suspended in THF (4.70 mL) cooled to 0 °C and Et₃SiH (1.44 mL, 9.04 mmol, 3.00 eq) was added. After 30 min the reaction mixture was allowed to warm to room temperature and stirred for additional 65 min. The reaction was stopped by filtration through a plug of celite and rinsed with EtOAc (100 mL). The solvent was evaporated under reduced pressure and the crude product was purified by column chromatography on silica (EtOAc) to give compound **13** (365 mg, 2.38 mmol, 79%) as pale yellow solid. The yield is only reproducible in this scale and under exact compliance with these reaction times. R_f =0.38 (EtOAc). ¹H-NMR (300 MHz, CDCl₃): δ =8.66 (s, 1H, CH_{arom}), 8.42 (s, 1H, CH_{arom}), 5.68 (s, 2H, NH₂), 4.01 (s, 3H, OCH₃) ppm. ¹³C-



NMR (75.5 MHz, DMSO-d6): $\delta = 166.6$ (1 C, COOCH₃), 148.8 (1 C, CH_{arom}), 145.2 (1 C, CH_{arom}), 143.5 (1 C, C_{arom}), 129.6 (1 C, C_{arom}), 52.0 (1 C, OCH₃) ppm. FT-IR: neat; $\tilde{\nu} = 3552$ (w), 3462 (m), 3264 (m), 3197 (m), 3137 (m), 3021 (w), 2952 (m), 2840 (w), 2124 (w), 1936 (w), 1840 (w), 1688 (m), 1608 (s), 1572 (m), 1461 (w), 1425 (s), 1442 (s), 1358 (w), 1327 (s), 1275 (m), 1205 (s), 1116 (s), 1047 (m), 970 (m), 901 (m), 870 (m), 814 (m), 713 (s), 668 (s), 599 (w), 541 (w), 462 (s), 420 (m) cm⁻¹. m.p.: 187°C (EtOAc). HRMS (ESI⁺): *m/z* calc. for C₆H₂N₃O₂Na₁ [M+Na]⁺: 176.0430, found: 176.0431.

5-Aminopyrimidine-4-carbaldehyde (14)



Pyrimidine ester 13 (590 mg, 3.85 mmol, 1.00 eq) was dissolved in CH₂Cl₂ (19.0 mL) and cooled to 0 °C before a solution of CeCl₃ • 7 H₂O (1.46 g, 3.93 mmol, 1.02 eg) in MeOH (19.0 mL) was added slowly. After 15 min NaBH₄ (583 mg, 15.4 mmol, 4.00 eg) was added portionwise (gas evolution). The reaction mixture was stirred for 1 h. Aqueous HCl (2 M, approx. 3 mL) was added until gas evolution stopped. All solvents were evaporated under reduced pressure and the crude product was purified by column chromatography on silica (CHCl₃/MeOH 9:1 to 8:1) to give the corresponding alcohol (410 mg, 3.28 mmol, 85%) as brown semisolid. $R_f = 0.20$ (CHCl₃/ MeOH 10:1). ¹H-NMR (300 MHz, DMSO-d6): $\delta = 8.33$ (s, 1H, CH_{arom}), 8.08 (s, 1H, CH_{arom}), 5.39 (s, 2H, NH₂), 5.29 (t, J=4.2 Hz, 1H, OH), 4.49 (d, J=4.0 Hz, 2H, CH₂) ppm. ¹³C-NMR (75.5 MHz, DMSO-d6): $\delta =$ 150.4 (1 C, C_{arom}), 146.3 (1 C, CH_{arom}), 141.9 (1 C, CH_{arom}), 140.4 (1 C, C_{arom}), 62.4 (1 C, CH₂) ppm. FT-IR: neat; $\tilde{v} = 3332$ (s), 3222 (s), 2842 (m), 2409 (w), 2195 (w), 2153 (w), 1738 (w), 1641 (m), 1574 (m), 1444 (m), 1411 (s), 1337 (m), 1261 (m), 1199 (m), 1141 (m), 1054 (s), 894 (m), 796 (w), 729 (m), 633 (m), 544 (m), 504 (m) cm⁻¹. m.p.: 159°C decomposition (MeOH). HRMS (ESI⁺): m/z calc. for $C_5H_7N_3O_1Na_1$ [M + Na]⁺: 148.0492, found: 148.0481. The obtained pyrimidine alcohol (50.0 mg, 400 µmol, 1.00 eq) was then dissolved in MeCN (8.00 mL) and MnO_2 (347 mg, 4.00 mmol, 10.0 eq) was added. The reaction mixture was stirred for 3 h at rt. before it was filtered over a pad of celite and rinsed with EtOAc (approx. 10 mL) until the filtrate turned colorless. The solvent was evaporated under reduced pressure. Due to decomposition during column chromatography the crude product was used without further purification. Compound 14 (40.0 mg, 324 µmol, 81%) was isolated as pale yellow solid. $R_f = 0.62$ (EtOAc). ¹H-NMR (500 MHz, CDCl₃): $\delta = 10.06$ (s, 1H, CHO), 8.72 (s, 1H, CH_{arom}), 8.45 (s, 1H, CH_{arom}), 5.91 (s, 2H, NH₂) ppm. ¹³C-NMR (75 MHz, DMSO-d6): δ = 195.9 (1 C, CHO), 149.3 (1 C, CH_{arom}), 145.8 (1 C, CH_{arom}), 142.0 (1 C, C_{arom}), 134.5 (1 C, C_{arom}) ppm. FT-IR: neat; $\tilde{v}\!=\!3407$ (m), 3285 (w), 3149 (m), 2878 (w), 2670 (w), 2083 (w), 1833 (w), 1689 (m), 1624 (s), 1572 (w), 1463 (w), 1424 (s), 1351 (w), 1299 (w), 1266 (w), 1181 (s), 1057 (m), 891 (s), 797 (w), 772 (m), 746 (w), 665 (s), 600 (w), 554 (w), 475 (s) cm⁻¹. m.p.: 174 °C (EtOAc). HRMS (ESI⁺): m/z calc. for $C_6H_9N_3O_2H_1$ [M+H]⁺: 156.0768, found: 156.0766.

5-Amino-2-(methylthio)pyrimidine-4-carbaldehyde (15)



Pyrimidine ester 12 (100 mg, 500 $\mu mol,$ 1.00 eq) was dissolved in THF (1.40 mL) and cooled to -20 $^\circ C$ before DIBAH (1 M in THF,

1.05 mL, 1.05 mmol, 2.10 eq) was added dropwise. The deep red reaction mixture was stirred for 2.5 h during which it warmed up to 10 °C. It was then cooled back to 0 °C before additional DIBAH (1 M in THF, 0.25 mL, 0.25 mmol, 0.50 eg) was added. After 1 h agueous HCl (2 M, approx. 5 mL) was added and extracted with EtOAc (20 mL). The organic phase was discarded, while the aqueous phase was added saturated aqueous NaHCO₃ solution (15 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were washed with brine (20 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (n-pentane/EtOAc 1:1 to EtOAc) to give the alcohol (76.0 mg, 440 µmol, 88%) as yellow solid. R_f=0.41 (CHCl₃/MeOH 8:1); R_f=0.25 (*n*-pentane/EtOAc 1:1). ¹H-NMR (500 MHz, DMSO-d6): δ = 8.03 (s, 1H, CH_{arom}), 5.31 (t, J = 5.8 Hz, 1H, OH), 5.16 (s, 2H, NH₂), 4.45 (d, J=5.9 Hz, 2H, CH₂), 2.43 (s, 3H, SCH₃) ppm. ¹³C-NMR (126 MHz, DMSO-d6): $\delta = 155.9$ (1 C, $C_{arom}SCH_3$), 152.5 (1 C, C_{arom}), 143.5 (1 C, CH_{arom}), 137.1 (1 C, C_{arom}), 62.4 (1 C, CH₂), 13.6 (1 C, SCH₃) ppm. FT-IR: neat; \tilde{v} = 3447 (w), 3410 (w), 3310 (w), 3204 (m), 2921 (w), 2835 (w), 2717 (w), 2607 (w), 2116 (w), 1865 (w), 1644 (m), 1578 (w), 1552 (m), 1458 (w), 1418 (m), 1368 (s), 1314 (w), 1280 (w), 1233 (w), 1207 (w), 1167 (w), 1090 (w), 1058 (w), 1036 (m), 993 (w), 970 (w), 918 (m), 786 (w), 752 (w), 724 (w), 661 (m), 577 (m), 475 (m) cm⁻¹. m.p.: 108 °C (MeOH). HRMS (ESI⁺): m/z calc. for $C_6H_9N_3O_1S_1Na_1$ [M + Na]⁺: 194.0359, found: 194.0359. The obtained pyrimidine alcohol (802 mg, 4.68 mmol, 1.00 eq) was dissolved in MeCN (80.0 mL) and MnO₂ (4.07 q. 46.8 mmol, 10.0 eg) was added. The reaction mixture was stirred for 2 h at rt before it was filtered over a pad of celite and rinsed with EtOAc (approx. 50 mL) until the filtrate turned colorless. The solvent was evaporated under reduced pressure. Due to decomposition during column chromatography the crude product was used without further purification. Compound 15 (626 mg, 3.70 mmol, 80%) was isolated as highly yellow solid. $R_f = 0.79$ (EtOAc). ¹H-NMR (500 MHz, CDCl₃): $\delta = 10.02$ (d, J = 0.7 Hz, 1H, CHO), 8.35 (d, J =0.7 Hz, 1H, CH_{arom}), 5.68 (s, 2H, NH₂), 2.59 (s, 3H, SCH₃) ppm. ¹³C-NMR (75 MHz, DMSO-d6): $\delta = 195.2$ (1 C, CHO), 155.4 (1 C, C_{arom}SCH₃), 151.1 (1 C, CH_{arom}), 139.2 (1 C, C_{arom}), 135.4 (1 C, C_{arom}), 13.6 (1 C, SCH₃) ppm. FT-IR: neat; \tilde{v} = 3416 (m), 3273 (m), 3198 (w), 3159 (w), 2928 (w), 2838 (w), 2711 (w), 2083 (w), 1853 (w), 1668 (m), 1615 (s), 1566 (m), 1477 (w), 1415 (s), 1401 (w), 1313 (w), 1283 (w), 1186 (m), 1147 (s), 1055 (w), 969 (w), 930 (w), 902 (m), 775 (m), 760 (w), 735 (w), 719 (m), 644 (m), 460 (m), 438 (w), 413 (w) cm⁻¹. m.p.: 137 °C (EtOAc). HRMS (ESI⁺): m/z calc. for $C_6H_7N_3O_1S_1Na_1$ [M+Na]⁺: 192.0202, found: 192.0202.

Ethyl (Z)-3-(5-aminopyrimidin-4-yl)-2-bromoacrylate (17-(Z))



Phosphonate **16** (X=OEt, 515 mg, 1.70 mmol, 1.10 eq) and 18crown-6 (494 mg, 1.85 mmol, 1.20 eq) were dissolved in THF (15.0 mL) and cooled to -20 °C. KOtBu (186 mg, 1.62 mmol, 1.05 eq) was added portionwise. After 30 min aldehyde **14** (190 mg, 1.54 mmol, 1.00 eq) was added as solid and the resulting deep brown reaction mixture was stirred for 2.5 h while reaching 0 °C. The reaction mixture was poured into saturated aqueous NH₄Cl solution (15 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were washed with brine (30 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (CHCl₃/MeOH 10:1) to give exclusively **17**-(*Z*) (348 mg, 1.28 mmol, 83%) as yellow solid. R_f=0.20 (*n*-pentane/



EtOAc 1:2). ¹H-NMR (500 MHz, CDCl₃): δ = 8.73 (s, 1H, *CH*_{arom}), 8.30 (s, 1H, *CH*_{arom}), 8.14 (s, 1H, *CH*_{olef}), 4.37 (q, *J* = 7.1 Hz, 2H, *CH*₂CH₃), 3.89 (s, 2H, NH₂), 1.39 (t, *J* = 7.1 Hz, 3H, CH₂CH₃) ppm. ¹³C-NMR (126 MHz, CDCl₃): δ = 162.2 (1 C, COOEt), 149.2 (1 C, *CH*_{arom}), 145.4 (1 C, *CH*_{arom}), 144.5 (1 C, *C*_{arom}), 138.2 (1 C, *C*_{arom}), 135.0 (1 C, *CH*_{olef}), 121.0 (1 C, *CBr*_{olef}), 63.5 (1 C, *CH*₂CH₃), 14.3 (1 C, *CH*₂CH₃) ppm. FT-IR: neat; \tilde{v} = 3434 (w), 3321 (w), 3196 (m), 2972 (w), 2853 (w), 2719 (w), 2107 (w), 1899 (w), 1714 (s), 1647 (w), 1569 (w), 1537 (m), 1449 (w), 1411 (s), 1365 (w), 1343 (w), 1300 (w), 1280 (w), 1248 (s), 1209 (w), 1183 (w), 1166 (w), 1120 (w), 1092 (w), 1023 (s), 968 (w), 904 (m), 860 (w), 831 (w), 798 (w), 769 (w), 744 (w), 726 (w) cm⁻¹. m.p.: 80 °C (EtOAc). HRMS (ESI⁺): *m/z* calc. for C₉H₁₀Br₁N₃O₂H₁ [M+H]⁺: 272.0029 & 274.0009, found: 272.0030 & 274.0010.

Methyl (*Z*)-3-(5-aminopyrimidin-4-yl)-2-bromoacrylate (17 a-(*Z*))



Phosphonate 16a (99.2 mg, 250 µmol, 1.10 eg) and 18-crown-6 (72.7 mg, 272 µmol, 1.20 eg) were dissolved in THF (2.00 mL) and cooled to -20°C. KOtBu (27.3 mg, 238 µmol, 1.05 eg) was added portionwise. After 30 min aldehyde 14 (30.0 mg, 227 µmol, 1.00 eq) was added as solid and the resulting deep brown reaction mixture was stirred for 25 min. The reaction mixture was poured into saturated aqueous NH₄Cl solution (5 mL) and extracted with EtOAc $(3 \times 10 \text{ mL})$. The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (n-pentane/EtOAc 1:2) to give a mixture of 17 a-(Z) (43.0 mg, 167 µmol, 73%) and traces of 17 a-(E) as yellow solid. Data for pure **17 a**-(*Z*): $R_f = 0.16$ (*n*-pentane/EtOAc 1:2). ¹H-NMR (500 MHz, CDCl₃): $\delta = 8.75$ (s, 1H, CH_{arom}), 8.31 (s, 1H, CH_{arom}), 8.15 (s, 1H, CH_{olef}), 3.93 (s, 3H, CH₃), 3.89 (s, 2H, NH₂) ppm. ¹³C-NMR (126 MHz, CDCl₃): δ = 162.8 (1 C, COOMe), 149.2 (1 C, CH_{arom}), 145.4 (1 C, CH_{arom}), 144.4 (1 C, C_{arom}), 138.2 (1 C, C_{arom}), 135.2 (1 C, CH_{olef}), 120.3 (1 C, CBr_{olef}), 54.1 (1 C, CH₃) ppm. FT-IR: neat; $\tilde{v} = 3584$ (w), 3410 (m), 3326 (w), 3181 (w), 3018 (w), 2955 (w), 2923 (w), 2853 (w), 2718 (w), 2120 (w), 1894 (w), 1716 (m), 1655 (s), 1593 (w), 1568 (w), 1535 (m), 1449 (w), 1413 (s), 1347 (w), 1295 (w), 1254 (s), 1213 (w), 1184 (w), 1127 (w), 1076 (w), 1029 (m), 1004 (w), 952 (w), 935 (w), 898 (m), 828 (w), 766 (w), 736 (m) cm⁻¹. m.p.: 159 °C decomposition (EtOAc). HRMS (ESI⁺): m/z calc. for $C_8H_8Br_1N_3O_2H_1$ [M+H]⁺: 257.9873 & 259.9853, found: 257.9875 & 259.9855.

7-Bromopyrido[3,2-d]pyrimidin-6(5H)-one (18a)



Pyrimidine 17-(Z) (210 mg, 814 µmol, 1.00 eq) or pyrimidine 17 a-(Z) (52.0 mg, 201 µmol, 1.00 eq) was dissolved in MeOH (5 mM respectively) and heated to 60 °C for 3 h under irradiation of light (λ =435 nm). All solvents were evaporated under reduced pressure and the crude product was purified by column chromatography on silica (EtOAc) to give compound 18a (28.0 mg, 124 µmol, 62% for 17 a-(Z) or 145 mg, 642 µmol, 79% for 17-(Z)) as pale brownish solid. R_f=0.33 (EtOAc). ¹H-NMR (500 MHz, DMSO-d6): δ =12.68 (s, 1H, NH), 9.03 (s, 1H, CH_{arom}), 8.85 (s, 1H, CH_{arom}), 8.53 (s, 1H, CH_{arom}) ppm. ¹³C-NMR (126 MHz, CDCl₃): δ =156.8 (1 C, NCO), 152.3 (1 C,

CH_{arom}), 145.6 (1 C, CH_{arom}), 141.1 (1 C, CH_{arom}), 140.4 (1 C, C_{arom}), 131.7 (1 C, C_{arom}), 128.3 (1 C, CBr_{arom}) ppm. FT-IR: neat; $\tilde{\nu}$ = 3312 (w), 3151 (w), 3000 (w), 2901 (w), 2830 (w), 2749 (m), 1931 (w), 1894 (w), 1758 (w), 1653 (s), 1588 (w), 1478 (w), 1443 (w), 1399 (m), 1354 (w), 1308 (w), 1216 (w), 1181 (m), 1155 (w), 1110 (w), 998 (m), 951 (w), 915 (w), 891 (s), 824 (w), 742 (m), 638 (m), 580 (s), 460 (m) cm⁻¹. m.p.: 231 °C decomposition (EtOAc). HRMS (APCI⁺): *m/z* calc. for C₇H₄Br₁N₃O₁H₁ [M+H]⁺: 225.9611 & 227.9590, found: 225.9612 & 227.9592.

Methyl (*Z*)-3-(5-aminopyrimidin-4-yl)-2-((tert-butoxycarbonyl) amino)-acrylate (17 b-(*Z*))



Phosphonate 16b (244 mg, 804 µmol, 1.10 eq) was dissolved in CH_2CI_2 (1.75 mL) and DBU (116 μ L, 768 μ mol, 1.05 eq) was added. After stirring for 5 min the solution was given to a solution of pyrimidine carbaldehyde 14 (90.0 mg, 731 µmol, 1.00 eg) in CH₂Cl₂ (3.00 mL). The highly fluorescent yellow reaction mixture was stirred for 7 h at rt before it was poured into saturated aqueous NH₄Cl solution (5 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (10 mL), dried over Na2SO4 and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (*n*-pentane/EtOAc 1:2) to give a mixture of 17 b-(Z)and the cyclized compound 18b which comes from in situ cyclisation of 17 b-(E) (overall 223 mg, 99%) as highly yellow solid. The ratio of **17**b-(Z) to pyridopyrimidine **18**b is 16.8:1 which should reflect the Z/E ratio during the reaction. Data for pure 17b-(Z): $R_f = 0.30$ (*n*-pentane/EtOAc 1:2). ¹H-NMR (600 MHz, CDCl₃): $\delta =$ 10.74 (s, 1H, NHBoc) 8.65 (s, 1H, CH_{arom}), 8.18 (s, 1H, CH_{arom}), 6.05 (s, 1H, CH_{olef}), 3.88 (s, 3H, CH₃), 3.83 (s, 2H, NH₂), 1.49 (s, 9H, C(CH₃)₃) ppm. ¹³C-NMR (75.5 MHz, CDCl₃): $\delta = 165.8$ (1 C, COOMe), 152.3 (CNHBoc), 148.6 (1 C, CH_{arom}), 146.5 (1 C, C_{arom}), 144.4 (1 C, CH_{arom}), 137.6 (1 C, C_{arom}), 137.5 (1 C, N(CO)O), 103.5 (1 C, CH_{olef}), 81.5 (1 C, $C(CH_3)_3$, 52.9 (CH₃), 28.3 (3 C, $C(CH_3)_3$) ppm. FT-IR: neat; $\tilde{v} = 3460$ (m), 3373 (m), 3258 (w), 3070 (w), 3003 (w), 2979 (w), 2951 (w), 1727 (w), 1706 (s), 1648 (w), 1629 (m), 1562 (w), 1545 (m), 1437 (s), 1411 (w), 1369 (w), 1335 (w), 1300 (m), 1277 (w), 1243 (m), 1210 (w), 1151 (s), 1061 (m), 1033 (w), 987 (w), 905 (w), 879 (w), 850 (w), 810 (m), 777 (w), 753 (m), 718 (w), 669 (w) cm⁻¹. m.p.: 205 °C decomposition (CHCl₃). HRMS (ESI⁺): m/z calc. for C₁₃H₁₈N₄O₄H₁ [M+H]⁺: 295.1401, found: 295.1402.

tert-Butyl (6-oxo-5,6-dihydropyrido[3,2-*d*]pyrimidin-7-yl) carbamate (18 b)



Pyrimidine **17** b-(*Z*) (665 mg, 2.26 mmol, 1.00 eq) was dissolved in MeOH (90.0 mL) and heated to 65 °C for 5.5 h under irradiation of light (λ =435 nm). All solvents were evaporated under reduced pressure and the crude product was purified by column chromatography on silica (EtOAc/MeOH 10:1) to give compound **18** b (590 mg, 2.25 µmol, 99%) as pale yellow solid. R_f=0.22 (*n*-pentane/EtOAc 1:3). ¹H-NMR (500 MHz, DMSO-d6): δ =12.64 (s, 1H, NH), 8.94 (s, 1H, CH_{arom}), 8.71 (s, 1H, CH_{arom}), 8.41 (s, 1H, NHCO₂tBu), 8.13 (s, 1H, CH_{arom}), 1.50 (s, 9H, C(CH₃)₃) ppm. ¹³C-NMR (126 MHz, DMSO-d6): δ =

156.1 (1 C, NCO), 152.7 (1 C, CH_{arom}), 151.8 (1 C, C_{arom}), 143.7 (1 C, CH_{arom}), 142.8 (1 C, CO_2NH), 136.6 (1 C, C_{arom}), 127.3 (1 C, C_{arom}), 115.2 (1 C, CH_{arom}), 81.4 (1 C, $C(CH_3)_3$), 27.8 (3 C, $C(CH_3)_3$) ppm. FT-IR: neat; $\tilde{v} = 3390$ (w), 3310 (w), 2972 (w), 2940 (w), 2851 (w), 1734 (m), 1649 (s), 1611 (w), 1590 (w), 1559 (w), 1506 (s), 1451 (w), 1369 (m), 1303 (w), 1253 (m), 1192 (w), 1145 (s), 1032 (s), 948 (w), 926 (w), 898 (m), 850 (m), 787 (w), 762 (w), 705 (m), 635 (w), 610 (m), 591 (w), 521 (w), 463 (w), 439 (w) cm⁻¹. m.p.: 331°C decomposition (CHCl₃). HRMS (ESI⁺): m/z calc. for $C_{12}H_{14}N_4O_3H_1$ [M+H]⁺: 263.1139, found: 263.1140.

(Z)-4-(5-Aminopyrimidin-4-yl)-3-bromobut-3-en-2-one (17 c-(Z))



Compound 17 c-(Z) was synthesized starting from phosphonate 16 c or phosphonate 16 d.

Phosphonate **16c** (442 mg, 1.80 mmol, 1.15 eq) and 18-crown-6 (502 mg, 1.88 mmol, 1.20 eq) were dissolved in THF (15.0 mL) and cooled to -20 °C. KOtBu (189 mg, 1.65 mmol, 1.05 eq) was added portionwise. After 15 min aldehyde **14** (193 mg, 1.57 mmol, 1.00 eq) in THF (15.0 mL) was added dropwise. The resulting deep orange to brown reaction mixture was stirred for 16 h while reaching rt. The reaction mixture was poured into saturated aqueous NH₄Cl solution (20 mL) and extracted with EtOAc (3×40 mL). The combined organic layers were washed with brine (40 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (*n*-pentane/EtOAc 1:2) to give a 4:1 mixture of **17c**-(*Z*) to **17c**-(*E*) (overall: 258 mg, 1.07 mmol, 68%) as orange solid.

Or:

Phosphonate 16d (476 mg, 1.74 mmol, 1.43 eq) and 18-crown-6 (390 mg, 1.46 mmol, 1.20 eq) were dissolved in THF (10.0 mL) and cooled to -20°C. KOtBu (147 mg, 1.28 mmol, 1.05 eg) was added portionwise. After 15 min aldehyde 14 (150 mg, 1.22 mmol, 1.00 eg) in THF (10.0 mL) was added dropwise. The resulting deep orange to brown reaction mixture was stirred for 16 h while reaching rt. The reaction mixture was poured into saturated aqueous NH₄Cl solution (20 mL) and extracted with EtOAc (3×40 mL). The combined organic layers were washed with brine (40 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (npentane/EtOAc 1:2) to give a 1.3:1 mixture of 17c-(Z) to 17c-(E)(overall: 192 mg, 793 μmol, 65%) as orange solid. Data for 17 c-(Z): $R_f = 0.38$ (E) & 0.29 (Z) (EtOAc). ¹H-NMR (500 MHz, CDCl₃): $\delta = 8.74$ (s, 1H, CH_{arom}), 8.32 (s, 1H, CH_{arom}), 7.96 (s, 1H, CH_{olef}), 3.93 (s, 2H, NH₂), 2.63 (s, 3H, CH₃) ppm. ¹³C-NMR (126 MHz, CDCl₃): δ = 192.8 (1 C, CO), 149.0 (1 C, CH_{arom}), 145.4 (1 C, CH_{arom}), 144.6 (1 C, C_{arom}), 138.3 (1 C, C_{arom}), 133.2 (1 C, CH_{olef}), 129.4 (1 C, CBr_{arom}), 27.3 (1 C, CH₃) ppm. FT-IR: neat; $\tilde{v} = 3001$ (m), 3326 (w), 3200 (m), 3008 (w), 2920 (w), 1837 (w), 1683 (m), 1647 (m), 1610 (m), 1564 (m), 1541 (m), 1487 (m), 1461 (m), 1415 (w), 1358 (w), 1335 (s), 1304 (m), 1275 (w), 1247 (w), 1216 (s), 1191 (m), 1125 (m), 1062 (w), 1012 (m), 979 (m), 943 (m), 910 (w), 848 (m), 826 (m), 804 (m), 777 (w), 757 (w), 715 (w), 674 (w), 642 (w), 619 (m), 565 (m), 463 (w), 439 (w) cm⁻¹. m.p.: 125 °C decomposition (EtOAc). HRMS (ESI⁺): m/z calc. for C₈H₈Br₁N₃O₁H₁ [M + H]⁺: 241.9924, found: 241.9924.

7-Bromo-6-methylpyrido[3,2-d]pyrimidine (18 c)



Pyrimidine 17 c - (Z) (254 mg, 863 µmol, 1.00 eq) was dissolved in MeOH (180 mL) and heated to 60 °C for 3.5 h under irradiation of light (λ = 435 nm). All solvents were evaporated under reduced pressure and the crude product was purified by column chromatography on silica (n-pentane/EtOAc 1:1 to 1:2) to give compound **18c** (162 mg, 723 μ mol, 84%) as pale brownish solid. R_f=0.66 (EtOAc). ¹H-NMR (500 MHz, CDCl₃): $\delta = 9.54$ (s, 1H, CH_{arom}), 9.34 (s, 1H, CH_{arom}), 8.54 (s, 1H, CH_{arom}), 2.92 (s, 3H, CH₃) ppm. ¹³C-NMR (126 MHz, CDCl₃): $\delta = 161.1$ (1 C, NCCH₃), 161.0 (1 C, CH_{arom}), 155.9 (1 C, CH_{arom}), 145.9 (1 C, C_{arom}), 139.0 (1 C, CH_{arom}), 138.6 (1 C, C_{arom}), 127.3 (1 C, CBr_{arom}), 26.2 (1 C, CH₃) ppm. FT-IR: neat; $\tilde{v} =$ 3204 (w), 3051 (w), 2924 (w), 2532 (w), 2396 (w), 2336 (w), 2151 (w), 1985 (w), 1913 (w), 1858 (w), 1688 (w), 1588 (w), 1565 (m), 1547 (w), 1493 (w), 1452 (w), 1435 (w), 1401 (s), 1376 (w), 1351 (w), 1318 (w), 1281 (w), 1251 (w), 1220 (w), 1169 (w), 1082 (m), 1028 (w), 977 (s), 939 (m), 916 (w), 794 (w), 722 (w), 676 (s) cm⁻¹. m.p.: 134°C (EtOAc). HRMS (ESI⁺): *m/z* calc. for $C_8H_6Br_1N_3H_1$ [M+H]⁺: 223.9818 & 225.9797, found: 223.9818 & 225.9798.

Methyl (Z)-3-(5-amino-2-(methylthio) pyrimidin-4-yl)-2-((tert-butoxy-carbonyl)amino)acrylate (17 d-(Z))

BocHN_CO₂Me

Phosphonate 16b (592 mg, 1.95 mmol, 1.10 eq) was dissolved in CH₂Cl₂ (20.0 mL) and DBU (283 µL, 1.86 mmol, 1.05 eq) was added. After stirring for 5 min the solution was given to a solution of pyrimidine carbaldehyde 15 (300 mg, 1.77 mmol, 1.00 eq) in CH₂Cl₂ (15.0 mL). The highly fluorescent yellow reaction mixture was stirred for 1 h at rt before it was poured into saturated aqueous NH₄Cl solution (30 mL) and extracted with CHCl₃ (3×30 mL). The combined organic lavers were washed with brine (30 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (n-pentane/EtOAc 2:1 to 1:1) to give a mixture of 17 d-(Z) (494 mg, 1.45 mmol, 82%) and the cyclized compound 18 d (38.0 mg, 123 mmol, 7%) which comes from in situ cyclisation of 17d-(E) (overall 89%) both as highly yellow solid. The ratio of 17d-(Z) to pyridopyrimidine **18d** is 11.7:1 which should reflect the Z/E ratio during the reaction. Data for pure 17 d - (Z): $R_f = 0.53$ (*n*pentane/EtOAc 1:2). ¹H-NMR (500 MHz, CDCl₃): $\delta = 10.88$ (s, 1H, NHCO2tBu), 8.12 (s, 1H, CHarom), 6.03 (s, 1H, CHolef), 3.89 (s, 3H, CO2CH3), 2.80 (s, 2H, NH2), 2.59 (s, 3H, SCH3), 1.49 (s, 9H, C(CH3)3) ppm. $^{13}\text{C-NMR}$ (126 MHz, CDCl₃): $\delta\!=\!$ 165.5 (1 C, CO_2CH_3), 160.2 (1 C, C_{arom}SCH₃), 151.9 (1 C, CO₂NH), 148.2 (1 C, C_{arom}), 145.6 (1 C, CH_{arom}), 137.8 (1 C, C_{arom}), 134.1 (1 C, C_{arom}), 103.0 (1 C, CH_{olef}), 82.0 (1 C, C(CH₃)₃), 53.0 (1 C, CO₂CH₃), 28.2 (3 C, C(CH₃)₃), 14.7 (1 C, SCH₃) ppm. FT-IR: neat; $\tilde{v} = 3451$ (w), 3367 (m), 3251 (w), 2983 (w), 2927 (w), 1729 (w), 1706 (s), 1644 (w), 1623 (w), 1557 (w), 1539 (w), 1457 (w), 1432 (w), 1396 (s), 1369 (w), 1291 (m), 1248 (w), 1225 (m), 1133 (s), 1083 (w), 1062 (w), 1032 (w), 982 (w), 962 (w), 938 (w), 872 (w), 848 (w), 810 (m), 774 (m), 753 (w), 714 (w), 667 (w), 636 (w), 605 (w), 557 (w), 492 (w) cm⁻¹. m.p.: 175 °C (EtOAc). HRMS (ESI⁺): *m/z* calc. for C₁₄H₂₀N₄O₄S₁Na₁ [M + Na]⁺: 363.1097, found: 363.1098.

Eur. J. Org. Chem. 2021, 1–20

www.eurjoc.org



tert-Butyl (2-(methylthio)-6-oxo-5,6-dihydropyrido[3,2-*d*] pyrimidin-7-yl)carbamate (18 d)



Pyrimidine 17 d-(Z) (48.0 mg, 140 μ mol, 1.00 eg) was dissolved in MeOH (7.00 mL) and heated to 60 °C for 2 h under irradiation of light (λ =435 nm). All solvents were evaporated under reduced pressure and the crude product was purified by column chromatography on silica (n-pentane/EtOAc 1:1 to 1:2) to give compound 18d (42.0 mg, 140 µmol, 99%) as yellow solid. R_f=0.70 (*n*-pentane/ EtOAc 1:2). ¹H-NMR (500 MHz, CDCl₃): $\delta = 11.75$ (s, 1H, NH), 8.72 (s, 1H, CH_{arom}), 8.45 (s, 1H, CH_{arom}), 7.97 (s, 1H, NHCO₂tBu), 2.62 (s, 3H, SCH₃), 1.57 (s, 9H, C(CH₃)₃) ppm. ¹³C-NMR (126 MHz, CDCl₃): $\delta =$ 166.5 (1 C, C_{arom}SCH₃), 157.4 (1 C, CONH), 151.9 (1 C, CO₂NH), 145.4 (1 C, C_{arom}), 144.0 (1 C, CH_{arom}), 136.9 (1 C, C_{arom}), 123.2 (1 C, C_{arom}), 116.8 (1 C, CH_{arom}), 82.7 (1 C, $C(CH_3)_3$), 28.3 (3 C, $C(CH_3)_3$), 14.6 (1 C, SCH₃) ppm. FT-IR: neat; \tilde{v} = 3390 (w), 2971 (w), 2874 (w), 2819 (w), 2761 (w), 1734 (w), 1653 (m), 1605 (w), 1583 (w), 1563 (w), 1507 (m), 1434 (w), 1369 (s), 1312 (m), 1277 (w), 1252 (m), 1234 (w), 1207 (w), 1146 (s), 1049 (w), 1019 (w), 935 (w), 901 (m), 865 (w), 805 (w), 765 (w), 725 (m), 634 (m), 597 (m), 539 (m), 428 (w), 415 (w) cm⁻¹. m.p.: 342°C decomposition (EtOAc). HRMS (ESI+): m/z calc. for C₁₃H₁₆N₄O₃S₁Na₁ [M + Na]⁺: 331.0835, found: 331.0834.

Ethyl (Z)-3-(5-amino-2-(methylthio) pyrimidin-4-yl)-2-chloroacrylate (17 e-(Z))



Phosphonate 16e (714 µL, 3.24 mmol, 1.05 eq) and 18-crown-6 (906 mg, 3.39 mmol, 1.10 eq) were dissolved in THF (15.0 mL) and cooled to -20 °C. KOtBu (371 mg, 3.24 mmol, 1.05 eq) was added portionwise. After 15 min aldehyde 15 (522 mg, 3.09 mmol, 1.00 eq) in THF (5.00 mL) was added dropwise. The resulting deep orange to brown reaction mixture was stirred for 30 min. The reaction mixture was poured into saturated aqueous NH₄Cl solution (20 mL) and extracted with EtOAc (3×30 mL). The combined organic layers were washed with brine (30 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The solid orange crude product which is a mixture of 17 e-(Z), cyclized compound 18 e which comes from in situ cyclisation of 17 e-(E) - and phosphonate 16e was used for the next reaction without further purification. The yield is given over two steps. Data for pure $17 e^{-(Z)}$: $R_f = 0.35$ (npentane/EtOAc 1:1). ¹H-NMR (500 MHz, CDCl₃): $\delta = 8.18$ (s, 1H, CH_{arom}), 7.81 (s, 1H, CH_{olef}), 4.37 (q, J=7.2 Hz, 2H, CH₂), 3.73 (s, 2H, NH₂), 2.55 (s, 3H, SCH₃), 1.38 (t, J=7.2 Hz, 3H, CH₃) ppm. ¹³C-NMR (126 MHz, CDCl₃): δ = 162.4 (1 C, CO₂Et), 161.0 (1 C, C_{arom}SCH₃), 147.3 (1 C, CH_{arom}), 144.6 (1 C, C_{arom}), 135.1 (1 C, C_{arom}), 130.5 (1 C, CH_{olef}), 129.3 (1 C, C_{arom}Cl), 63.2 (1 C, CH₂), 14.6 (1 C, SCH₃), 14.3 (1 C, CH₃) ppm. FT-IR: neat; $\tilde{v} = 3419$ (m), 3319 (w), 3216 (w), 3046 (w), 2990 (w), 2945 (w), 2919 (w), 2722 (w), 2294 (w), 2241 (w), 2107 (w), 1983 (w), 1693 (w), 1643 (w), 1601 (w), 1576 (w), 1521 (w), 1470 (w), 1402 (w), 1361 (w), 1322 (w), 1277 (w), 1233 (w), 1195 (w), 1142 (w), 1082 (w), 1040 (w), 1016 (w), 938 (w), 907 (w), 870 (w), 833 (w), 771 (w), 750 (w), 723 (w), 700 (w), 635 (w), 589 (w), 498 (w), 471 (w), 445 (w), 427 (w) cm⁻¹. m.p.: 132 °C (CHCl₃). HRMS (ESI⁺): *m/z* calc. for $C_{10}H_{12}CI_1N_3O_2S_1H_1$ [M + H]⁺: 274.0412, found: 274.0408.

7-Chloro-2-(methylthio)pyrido[3,2-*d*]pyrimidin-6(5*H*)-one (18 e)

The crude pyrimidine 17 e(Z) (850 mg) was dissolved in MeOH (300 mL) and was divided into two different flasks which were irradiated simultaneously. The two reaction mixtures were heated to 60 °C for 7 h under irradiation of light (λ = 435 nm). The combined reaction mixtures were concentrated until a yellow precipitate formed. It was cooled to 0°C, filtered and washed with cold n-pentane/EtOAc (10:1, 50 mL). The filter cake consisted of pure compound 18e (575 mg, 2.53 mmol, 82% over two steps), while there was still product in the filtrate left. All solvents were evaporated under reduced pressure and the crude product which consisted of trace amounts of OEt compound (no pyridone, but NCOEt), compound 18e and phosphonate 16e (212 mg) was subjected to a saponification reaction. Therefore NaOH (425 mg, 10.6 mmol, 3.27 eq related to phosphonate 16e) was added to a mixture of crude product in THF (5.00 mL) and H₂O (0.50 mL) and stirred for 2 h. The reaction mixture was poured into saturated aqueous NaHCO₃ solution (5 mL) and extracted with EtOAc (3 \times 10 mL). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (n-pentane/EtOAc 1:1 to EtOAc) to give additional compound 18e (120 mg, 527 µmol, 17%, 99% combined yield over two steps). $R_f = 0.27$ (*n*-pentane/EtOAc 1:1). ¹H-NMR (500 MHz, DMSO-d6): δ = 12.60 (s, 1H, OCNH), 8.70 (s, 1H, CH_{arom}), 8.22 (s, 1H, CH_{arom}), 2.55 (s, 3H, SCH₃) ppm. ¹³C-NMR (126 MHz, DMSO-d6): $\delta = 164.2$ (1 C, $C_{arom}SCH_3$), 156.2 (1 C, $C_{arom}Cl$), 146.3 (1 C, CH_{arom}), 141.2 (1 C, C_{arom}), 136.4 (1 C, CON), 136.3 (1 C, CH_{arom}), 128.2 (1 C, C_{arom}), 13.7 (1 C, SCH₃) ppm. FT-IR: neat; $\tilde{v} = 3132$ (w), 3042 (w), 2827 (m), 2762 (w), 1656 (s), 1597 (w), 1575 (m), 1463 (w), 1414 (m), 1377 (s), 1317 (w), 1225 (w), 1196 (m), 1143 (s), 1029 (m), 967 (w), 928 (m), 891 (w), 861 (w), 770 (w), 750 (w), 724 (w), 639 (s), 589 (m), 541 (m), 417 (m) cm⁻¹. m.p.: 253 °C (EtOAc). HRMS (ESI⁺): *m/z* calc. for $C_8H_6CI_1N_3O_1S_1Na_1$ [M + Na]⁺: 249.9812, found: 249.9809.

Ethyl (Z)-3-(5-amino-2-(methylthio) pyrimidin-4-yl)-2-bromoacrylate (17 f-(Z))



Phosphonate 16f (1.18 g, 3.90 mmol, 1.10 eg) and 18-crown-6 (1.14 g, 4.26 mmol, 1.20 eq) were dissolved in THF (16.0 mL) and cooled to -20°C. KOtBu (426 mg, 3.72 mmol, 1.05 eq) was added portionwise. After 15 min aldehyde 176 (600 mg, 3.55 mmol, 1.00 eq) in THF (8.00 mL) was added dropwise. The resulting deep orange to brown reaction mixture was stirred for 2.5 h. The reaction mixture was poured into saturated aqueous NH₄Cl solution (20 mL) and extracted with EtOAc (3×30 mL). The combined organic layers were washed with brine (30 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (n-pentane/EtOAc 1:1) to give a mixture of 17 f(Z) and the cyclized compound 18 fwhich comes from *in situ* cyclisation of **17f**-(*E*) both as orange solid. This mixture was used for the next reaction and the yield is given over two steps. Data for pure 17f(Z): $R_f = 0.30$ (*n*-pentane/EtOAc 1:1). ¹H-NMR (500 MHz, CDCl₃): $\delta = 8.17$ (s, 1H, CH_{arom}), 8.09 (s, 1H,



CH_{arom}), 4.34 (q, *J*=7.1 Hz, 2H, CH₂), 3.79 (s, 2H, NH₂), 2.55 (s, 3H, SCH₃), 1.36 (t, *J*=7.2 Hz, 3H, CH₃) ppm. ¹³C-NMR (126 MHz, CDCI₃): δ = 162.4 (1 C, COOCH₂), 160.7 (1 C, C_{arom}SCH₃), 147.2 (1 C, CH_{arom}), 145.3 (1 C, C_{arom}), 135.0 (1 C, C_{arom}), 134.1 (1 C, CH_{arom}), 120.5 (1 C, CBr), 63.4 (1 C, CH₂), 14.6 (1 C, SCH₃), 14.2 (1 C, CH₃) ppm. FT-IR: neat; \tilde{v} = 3419 (m), 3317 (w), 3212 (w), 3035 (w), 2989 (w), 2921 (w), 2721 (w), 2144 (w), 1691 (s), 1642 (w), 1595 (m), 1522 (m), 1470 (w), 1405 (s), 1363 (w), 1317 (w), 1275 (s), 1234 (w), 1197 (m), 1138 (w), 1083 (m), 1033 (m), 1008 (w), 939 (w), 908 (w), 870 (w), 830 (w), 772 (w), 748 (m), 685 (w), 626 (m), 588 (m), 504 (w) cm⁻¹. m.p.: 131 °C (CHCI₃). HRMS (ESI⁺): *m/z* calc. for C₁₀H₁₂Br₁N₃O₂S₁Na₁ [M+Na]⁺: 339.9726 & 341.9705, found: 339.9722 & 341.9702.

7-Bromo-2-(methylthio)pyrido[3,2-*d*]pyrimidin-6(5*H*)-one (18 f)



Crude pyrimidine 17 f-(Z) (933 mg) was dissolved in MeOH (200 mL) and heated to 60 °C for 4 h under irradiation of light (λ =435 nm). All solvents were evaporated under reduced pressure and the crude product was purified by column chromatography on silica (npentane/EtOAc 1:1 to EtOAc) to give OEt compound (no pyrimidone, but NCOEt, 113 mg, 377 µmol, 11% over two steps) and compound 18f (735 mg, 2.70 µmol, 77% over two steps) both as pale yellow solid. $R_f = 0.58$ (EtOAc). ¹H-NMR (500 MHz, DMSO-d6): $\delta\!=\!$ 12.58 (s, 1H, OH), 8.71 (s, 1H, CH $_{\rm arom}$), 8.44 (d, J $=\!$ 0.6 Hz, 1H, CH_{arom}), 2.55 (s, 3H, SCH₃) ppm. ¹³C-NMR (126 MHz, DMSO-d6): $\delta =$ 164.2 (1 C, $C_{arom}SCH_3$), 156.5 (1 C, $NC_{arom}O$), 146.6 (1 C, CH_{arom}), 141.3 (1 C, C_{arom}), 140.4 (1 C, CH_{arom}), 128.9 (1 C, C_{arom}), 128.7 (1 C, C_{arom}), 13.8 (1 C, SCH₃) ppm. FT-IR: neat; $\tilde{v} = 3128$ (w), 3037 (w), 2988 (w), 2927 (w), 2859 (w), 2823 (w), 2757 (w), 2197 (w), 2059 (w), 2035 (w), 1979 (w), 1865 (w), 1651 (s), 1597 (w), 1572 (m), 1462 (w), 1414 (m), 1379 (s), 1319 (w), 1258 (w), 1225 (w), 1195 (m), 1144 (s), 1041 (w), 1003 (m), 963 (w), 931 (m), 895 (w), 857 (w), 766 (w), 748 (w), 732 (w), 658 (w), 641 (w), 609 (m), 587 (m), 544 (m), 482 (w), 418(m) cm⁻¹. m.p.: 197 °C (EtOAc). HRMS (ESI⁻): m/z calc. for C₈H₅Br₁N₃O₁S₁ [M–H]⁻: 269.9342 & 271.9321, found: 269.9335 & 271.9316.

(Z)-4-(5-Aminopyrimidin-4-yl)-3-bromobut-3-en-2-one (17 g-(Z))



Compound **17g**-(*Z*) was synthesized starting from phosphonate **16c** or phosphonate **16d**.

Phosphonate **16c** (192 mg, 768 μ mol, 1.30 eq) and 18-crown-6 (189 mg, 709 mmol, 1.20 eq) were dissolved in THF (6.00 mL) and cooled to 0 °C. KOtBu (71.1 mg, 621 μ mol, 1.05 eq) was added portionwise. After 15 min aldehyde **15** (100 mg, 591 μ mol, 1.00 eq) in THF (5.00 mL) was added dropwise. The resulting deep orange to brown reaction mixture was stirred for 16 h while reaching rt. The reaction mixture was poured into saturated aqueous NH₄Cl solution (10 mL) and extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with brine (20 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (*n*-

pentane/EtOAc 2:1 to 1:1) to give 17g-(*Z*) (89.0 mg, 309 mmol, 53%) and the cyclized compound 18g (26.0 mg, 96 µmol, 16%) which comes from *in situ* cyclisation of 17g-(*E*) (overall 69%) both as orange solid. The ratio of 17g-(*Z*) to pyridopyrimidine 18g is 3.3:1 which should reflect the *Z*/*E* ratio during the reaction.

Or:

Phosphonate 16d (189 mg, 768 µmol, 1.30 eq) and 18-crown-6 (189 mg, 709 mmol, 1.20 eg) were dissolved in THF (6.00 mL) and cooled to 0°C. KOtBu (71.1 mg, 621 µmol, 1.05 eq) was added portionwise. After 15 min aldehyde 15 (100 mg, 591 µmol, 1.00 eq) in THF (5.00 mL) was added dropwise. The resulting deep orange to brown reaction mixture was stirred for 19 h during it reached rt. The reaction mixture was poured into saturated aqueous NH₄Clsolution (10 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were washed with brine (20 mL), dried over Na2SO4 and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (n-pentane/EtOAc 2:1 to 1:1) to give 17 g-(Z) (107 mg, 371 mmol, 63%) and the cyclized compound 18g (24.0 mg, 89 µmol, 15%) which comes from in situ cyclisation of 17 \mathbf{q} -(E) (overall 78%) both as orange solid. The ratio of 17 \mathbf{q} -(Z) to pyridopyrimidine 18g is 4.2:1 which should reflect the Z/E-ratio during the reaction. Data for pure $17 g_{-}(Z)$: R_f=0.10 (*n*-pentane/ EtOAc 2:1). ¹H-NMR (500 MHz, CDCl₃): $\delta = 8.20$ (s, 1H, CH_{arom}), 7.93 (s, 1H, CH_{arom}), 3.57 (s, 2H, NH₂), 2.62 (s, 3H, CH₃), 2.57 (s, 3H, SCH₃) ppm. $^{\rm 13}\text{C-NMR}$ (126 MHz, CDCl_3): $\delta\!=\!$ 193.0 (1 C, CO), 161.0 (1 C, C_{arom}SCH₃), 147.2 (1 C, CH_{arom}), 145.6 (1 C, C_{arom}), 135.0 (1 C, C_{arom}), 132.4 (1 C, CH_{arom}), 128.9 (1 C, CBr_{arom}), 27.4 (1 C, CH_3), 14.6 (1 C, SCH₃) ppm. FT-IR: neat; $\tilde{v} = 3398$ (w), 3321 (w), 3200 (m), 2997 (w), 2923 (w), 2108 (w), 2001 (w), 1927 (w), 1666 (s), 1594 (w), 1560 (w), 1523 (m), 1405 (s), 1298 (w), 1268 (w), 1226 (w), 1197 (s), 1131 (w), 1078 (w), 1011 (w), 971 (w), 935 (w), 921 (w), 892 (w), 862 (w), 810 (w), 767 (w), 676 (w), 650 (w), 620 (w), 597 (w), 556 (m), 507 (w), 442 (w) cm⁻¹. m.p.: 101 °C decomposition (EtOAc). HRMS (ESI⁺): m/z calc. for C₉H₈Br₁N₃S₁H₁ [M+H]⁺: 287.9801 & 289.9780, found: 287.9800 & 289.9780.

7-Bromo-6-methyl-2-(methylthio)pyrido[3,2-*d*]pyrimidine (18g)



Pyrimidine 17 g-(Z) (85.0 mg, 295 μ mol, 1.00 eq) was dissolved in MeOH (15.0 mL) and heated to 60 °C for 3.5 h under irradiation of light ($\lambda = 435$ nm). All solvents were evaporated under reduced pressure and the crude product was purified by column chromatography on silica (n-pentane/EtOAc 2:1) to give compound 18g (70.4 mg, 261 μ mol, 89%) as pale brownish solid. R_f=0.73 (npentane/EtOAc 2:1). ¹H-NMR (500 MHz, CDCl₃): $\delta = 9.30$ (s, 1H, CH_{arom}), 8.37 (s, 1H, CH_{arom}), 2.87 (s, 3H, CH₃), 2.67 (s, 3H, SCH₃) ppm. $^{13}\text{C-NMR}$ (126 MHz, CDCl_3): $\delta\!=\!170.3$ (1 C, $\textit{C}_{arom}\textit{SCH}_3$), 160.4 (1 C, CH_{arom}), 158.6 (1 C, C_{arom}), 146.5 (1 C, C_{arom}), 137.7 (1 C, CH_{arom}), 136.3 (1 C, C_{arom}), 127.5 (1 C, CBr_{arom}), 25.7 (1 C, CH₃), 14.8 (1 C, SCH₃) ppm. FT-IR: neat; $\tilde{v} = 3044$ (w), 2996 (w), 2956 (w), 2924 (m), 2853 (w), 2272 (w), 2054 (w), 1846 (w), 1726 (m), 1589 (m), 1553 (w), 1534 (s), 1431 (s), 1395 (m), 1362 (w), 1330 (w), 1284 (m), 1242 (w), 1181 (m), 1122 (s), 1071 (w), 1030 (w), 1006 (w), 972 (s), 955 (w), 925 (w), 822 (w), 797 (w), 754 (w), 698 (m), 651 (m), 594 (m), 548 (m), 510 (w), 481 (w), 425 (w) cm⁻¹. m.p.: 147 °C decomposition (EtOAc). HRMS (ESI⁺): m/z calc. for C₉H₈Br₁N₃S₁H₁ [M+H]⁺: 269.9695 & 271.9674, found: 269.9694 & 271.9673.

Eur. J. Org. Chem. 2021, 1–20

www.eurjoc.org

These are not the final page numbers! 77

10



7-Bromopyrido[3,2-*d*]pyrimidin-6-yl trifluoromethanesulfonate (19a)



Pyridopyrimidine 18a (35.0 mg, 155 µmol, 1.00 eg) was suspended in THF (1.00 mL) and Et₃N (30.0 μ L, 217 μ mol, 1.40 eq) was added. The suspension was cooled to 0 °C before TfCl (19.0 µL, 170 µmol, 1.10 eq) was added. The reaction mixture was stirred for 1 h while it was allowed to warm to rt. The brown reaction mixture was poured into saturated aqueous NH₄Cl solution (5 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (n- pentane/EtOAc 3:1) to give compound **19a** (30.0 mg, 72.0 µmol, 47%) as pale yellow solid. R_f=0.31 (n-pentane/EtOAc 3:1). ¹H-NMR (300 MHz, CDCl₃): $\delta = 9.59$ (d, J =0.7 Hz, 1H, CH_{arom}), 9.48 (s, 1H, CH_{arom}), 8.79 (d, J=0.7 Hz, 1H, CH_{arom}) ppm. ¹³C-NMR (76 MHz, CDCl₃): $\delta = 160.8$ (1 C, CH_{arom}), 157.5 (1 C, CH_{arom}), 151.3 (1 C, COTf_{arom}), 146.3 (1 C, C_{arom}), 144.9 (1 C, CH_{arom}), 136.7 (1 C, C_{arom}), 118.6 (q, J=321.0 Hz, 1 C, CF₃), 116.9 (1 C, CBr_{arom}) ppm. ¹⁹F-NMR (283 MHz, CDCl₃): $\delta = 72.7$ (s, 3F, CF₃) ppm. FT-IR: neat; ṽ = 3029 (w), 2926 (w), 1935 (w), 1697 (w), 1590 (w), 1572 (w), 1422 (s), 1402 (w), 1337 (w), 1310 (w), 1214 (s), 1188 (w), 1128 (m), 1084 (w), 999 (m), 955 (w), 924 (m), 905 (w), 853 (s), 801 (m), 769 (w), 746 (w), 688 (m), 634 (s), 604 (w), 585 (w), 568 (m), 541 (w), 500 (w), 478 (m), 423 (w) cm⁻¹. m.p.: 57 °C (EtOAc). HRMS (ESI⁺): m/z calc. for $C_8H_4Br_1F_3N_3O_3S_1$ [M+H]⁺: 357.9103 & 359.9083, found: 357.9112 & 359.9092.

7-Bromo-6-chloropyrido[3,2-d]pyrimidine (19b)



Pyridopyrimidine 18a (23.5 mg, 104 µmol, 1.00 eg) was dissolved in $POCl_3$ (190 μ L, 2.08 mmol, 20.0 eq) and heated to 85 °C for 20.5 h. The brown reaction mixture was poured into saturated aqueous NaHCO₃-solution (5 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (10 mL), dried over Na2SO4 and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (n-pentane/EtOAc 5:1) to give compound 19b (15.0 mg, 61.4 μ mol, 59%) as pale yellow solid. R_f=0.28 (*n*-pentane/ EtOAc 5:1). ¹H-NMR (500 MHz, CDCl₃): $\delta = 9.56$ (d, J = 0.8 Hz, 1H, CH_{arom}), 9.41 (s, 1H, CH_{arom}), 8.47 (dd, J=0.9, 0.5 Hz, 1H, CH_{arom}) ppm. ¹³C-NMR (126 MHz, CDCl₃): δ = 160.4 (1 C, CH_{arom}), 156.9 (1 C, CH_{arom}), 151.2 (1 C, CCI_{arom}), 145.8 (1 C, C_{arom}), 138.1 (1 C, C_{arom}), 137.9 (1 C, CH_{arom}), 136.0 (1 C, CBr_{arom}) ppm. FT-IR: neat; $\tilde{\nu}$ = 3419 (w), 3318 (w), 3216 (w), 3060 (w), 3025 (w), 2990 (w), 2959 (w), 2921 (m), 2852 (w), 1693 (w), 1644 (w), 1582 (m), 1561 (w), 1538 (w), 1442 (m), 1412 (s), 1384 (w), 1346 (w), 1323 (w), 1301 (w), 1277 (w), 1261 (m), 1216 (w), 1169 (w), 1137 (w), 1112 (w), 1079 (s), 1034 (w), 1017 (w), 981 (m), 941 (m), 907 (m), 798 (m), 751 (w), 693 (s), 658 (w), 635 (m), 600 (m), 557 (s), 519 (w), 483 (w), 455 (w) cm⁻¹. m.p.: 133 °C (EtOAc). HRMS (APCI⁺): *m/z* calc. for C₇H₃Br₁Cl₁N₃H₁ [M+H]⁺: 245.9249 & 243.9272, found: 245.9249 & 243.9269.

6,7-Dibromopyrido[3,2-*d*]pyrimidine (19c)



Pyridopyrimidine 18a (41.0 mg, 181 µmol, 1.00 eg) and POBr₃ (82.1 mg, 272 µmol, 1.50 eq) were mixed and heated to 140 °C for 16 h. The brown reaction mixture was allowed to cool to rt before it was diluted with saturated aqueous NaHCO₃ solution (5 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (n-pentane/EtOAc 1:2) to give compound **19c** (17.0 mg, 58.8 µmol, 33%) as brownish solid. $R_f = 0.67$ (*n*-pentane/EtOAc 1:2). ¹H-NMR (500 MHz, CDCl₃): $\delta = 9.58$ (s, 1H, CH_{arom}), 9.43 (s, 1H, CH_{arom}), 8.66 (s, 1H, CH_{arom}) ppm. ¹³C-NMR (126 MHz, CDCl₃): δ = 160.7 (1 C, CH_{arom}), 156.9 (1 C, CH_{arom}), 146.0 (1 C, C_{arom}), 145.7 (1 C, C_{arom}), 141.1 (1 C, CH_{arom}), 139.0 (1 C, CBr_{arom}), 129.3 (1 C, CBr_{arom}) ppm. FT-IR: neat; $\tilde{v} = 3368$ (w), 3021 (w), 2922 (s), 2852 (w), 2341 (w), 2100 (w), 1962 (w), 1928 (w), 1902 (w), 1860 (w), 1727 (w), 1670 (m), 1577 (m), 1553 (w), 1533 (w), 1466 (w), 1439 (m), 1410 (s), 1378 (w), 1340 (w), 1319 (w), 1300 (m), 1276 (w), 1211 (w), 1170 (w), 1119 (s), 1076 (m), 941 (s), 890 (w), 790 (w), 723 (w), 681 (m), 628 (s) cm⁻¹. m.p.: 183 °C (CHCl₃). HRMS (APCl⁺): *m/z* calc. for $C_7H_3Br_2N_3H_1$ [M+H]⁺: 287.8766 & 289.8746 & 291.8726, found: 287.8769 & 289.8748 & 291.8728.

7-((*tert*-Butoxycarbonyl)amino)pyrido[3,2-*d*] pyrimidin-6-yl4-methylbenzene-sulfonate (19d)



Pyridopyrimidine 18b (289 mg, 1.10 mmol, 1.00 eq) was dissolved in THF (11.0 mL) and Et₃N (214 μ L, 1.56 mmol, 1.40 eq) was added. The solution was cooled to 0°C before TosCl (233 mg, 1.21 mmol, 1.10 eq) and DMAP (13.6 mg, 110 µmol, 0.10 eq) was added. The reaction mixture was stirred for 2.5 h while it was allowed to warm to rt. The yellow reaction mixture was poured into saturated aqueous NH₄Cl-solution (10 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were washed with brine (20 mL). dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (n-pentane/EtOAc 2:1) to give compound 19d (375 mg, 901 µmol, 82%) as pale yellow solid. The position of the protecting group of compound 19d was proved by a crystal structure. R_f=0.26 (n-pentane/EtOAc 2:1). ¹H-NMR (500 MHz, CDCl₃): $\delta = 9.26$ (s, 1H, CH_{arom}), 9.16 (s, 1H, CH_{arom}), 8.99 (s, 1H, CH_{arom}), 8.14 (d, J=8.4 Hz, 2H, 2× CH_{arom}), 7.42 (d, J=8.1 Hz, 2H, 2× CH_{arom}), 7.28 (s, 1H, NHBoc), 2.48 (s, 3H, CH₃), 1.58 (s, 9H, C(CH₃)₃) ppm. ¹³C-NMR (126 MHz, CDCl₃): δ = 158.4 (1 C, CH_{arom}), 156.2 (1 C, CH_{arom}), 151.5 (1 C, N(CO)O), 147.3 (1 C, C_{arom}), 147.1 (1 C, C_{arom}), 146.7 (1 C, C_{arom}), 133.2 (1 C, C_{arom}), 132.5 (1 C, C_{arom}), 131.2 (1 C, C_{arom}), 129.9 (2 C, 2×CH_{arom}), 129.8 (2 C, 2×CH_{arom}), 122.9 (1 C, CH_{arom}), 83.2 (1 C, C(CH₃)₃), 28.3 (3 C, C(CH₃)₃), 22.0 (1 C, CH₃) ppm. FT-IR: neat; $\tilde{v} = 3358$ (w), 3100 (w), 2979 (w), 2923 (w), 1731 (m), 1601 (w), 1568 (w), 1515 (s), 1457 (w), 1422 (m), 1375 (m), 1346 (w), 1307 (w), 1248 (m), 1228 (w), 1195 (w), 1178 (w), 1157 (w), 1136 (s), 1090 (m), 1047 (w), 1018 (w), 946 (w), 921 (m), 856 (w), 808 (m), 785 (w), 730 (s), 701 (w), 659 (m), 616 (w), 587 (s), 546 (s) cm⁻¹. m.p.: 149 °C (EtOAc). HRMS (ESI⁺): m/z calc. for $C_{19}H_{20}N_4O_5S_1Na_1$ [M + Na]⁺ : 439.1047, found: 439.1050.



7-Bromo-2-(methylthio)pyrido[3,2-d]pyrimidin-6-yl trifluoromethanesulfonate (19 e)



Compound 18b (40.0 mg, 147 µmol, 1.00 eq) was dissolved in THF (1.50 mL) and cooled to 0 °C. DIPEA (50 µL, 294 µmol, 2.00 eq) was added. After 5 min TfCl (17 $\mu\text{L},$ 162 $\mu\text{mol},$ 1.10 eq) was added dropwise. The brown solution was stirred for 16 h during it warmed up to rt. It was poured into saturated aqueous NH₄Cl-solution (5 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (n-pentane/EtOAc 10:1 to EtOAc) to give compound 19e (27.0 mg, 67 µmol, 45%, 79% brsm) as yellow solid. $R_f = 0.78$ (*n*-pentane/EtOAc 5:1). ¹H-NMR (500 MHz, CDCl₃): $\delta = 9.26$ (d, J = 0.7 Hz, 1H, CH_{arom}), 8.87 (d, J = 0.7Hz, 1H, CH_{arom}), 2.67 (s, 3H, SCH₃) ppm. ¹³C-NMR (126 MHz, CDCl₃): $\delta = 172.9$ (1 C, C_{arom} SCH₃), 160.1 (1 C, CH_{arom}), 149.8 (1 C, C_{arom}SO₃CF₃), 146.9 (1 C, C_{arom}), 143.0 (1 C, CH_{arom}), 134.3 (1 C, C_{arom}), 118.6 (q, J=320.9 Hz, 1 C, CF₃), 117.1 (1 C, C_{arom}Br), 14.9 (1 C, SCH₃) ppm. ¹⁹F-NMR (283 MHz, CDCl₃): $\delta = -72.7$ (3F, CF₃) ppm. FT-IR: neat; $\tilde{v} = 3030$ (w), 2931 (w), 1591 (w), 1569 (w), 1535 (m), 1414 (s), 1377 (w), 1331 (m), 1309 (w), 1205 (s), 1123 (m), 1003 (s), 962 (w), 927 (w), 875 (m), 804 (s), 751 (m), 712 (m), 661 (w), 638 (m), 599 (m), 578 (w), 547 (w), 529 (w), 508 (w), 478 (w), 459 (w), 429 (w) cm⁻¹. m.p.: 90 °C (CHCl₃). HRMS (ESI⁺): m/z calc. for C₉H₆Br₁F₃N₃O₃S₂ [M + H]⁺: 405.8959 & 403.8981, found: 405.8958 & 403.8978.

7-Bromo-2-(methylthio)pyrido[3,2-*d*]pyrimidin-6-yl methanesulfonate (19f)

Compound 18f (100 mg, 367 µmol, 1.00 eq) was dissolved in CH₂Cl₂ (2.00 mL) and cooled to 0 °C. DMAP (9.0 mg, 73 µmol, 0.20 eq) and $Et_{3}N$ (102 μL , 735 $\mu mol,$ 2.00 eq) were added. After 5 min MsCl (34 µL, 441 µmol, 1.20 eq) was added dropwise. The solution was stirred for 1.5 h before it was poured into saturated aqueous NH₄Clsolution (5 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (npentane/EtOAc 2:1 to 1:1) to give compound 19f (129 mg, 368 μ mol, 99%) as yellow solid. R_f=0.63 (*n*-pentane/EtOAc 1:1). ¹H-NMR (500 MHz, CDCl₃): $\delta = 9.22$ (d, J = 0.8 Hz, 1H, CH_{arom}), 8.53 (d, J=0.8 Hz, 1H, CH_{arom}), 3.65 (s, 3H, OCH₃), 2.66 (s, 3H, SCH₃) ppm. ¹³C-NMR (126 MHz, CDCl₃): δ = 171.8 (1 C, C_{arom}SCH₃), 159.7 (1 C, CH_{arom}), 151.9 (1 C, C_{arom}), 146.6 (1 C, C_{arom}), 142.3 (1 C, CH_{arom}), 134.3 (1 C, C_{arom}), 118.4 (1 C, C_{arom}Br), 41.6 (1 C, SO₂CH₃), 14.8 (1 C, SCH₃) ppm. FT-IR: neat; $\tilde{v} = 2929$ (w), 2853 (w), 1734 (w), 1680 (w), 1638 (w), 1590 (w), 1565 (m), 1540 (w), 1419 (m), 1371 (s), 1313 (m), 1246 (w), 1214 (w), 1168 (s), 1127 (m), 1008 (m), 964 (m), 927 (w), 870 (s), 797 (s), 770 (w), 735 (m), 714 (w), 616 (m), 586 (w), 540 (s), 517 (w), 490 (w), 448 (w), 423 (w) cm⁻¹. m.p.: 136 °C (CH₂Cl₂). HRMS (ESI⁺): *m/z* calc. for $C_{9}H_{9}Br_{1}N_{3}O_{3}S_{2}$ [M + H]⁺: 349.9263 & 351.9242, found: 349.9264 & 351.9243

6,7-Dichloro-2-(methylthio)pyrido[3,2-d]pyrimidine (19g)



Pyridone 18f (100 mg, 439 µmol, 1.00 eq) was suspended in PhCl (0.89 mL) and cooled to 10 °C before DIPEA (90 µL, 527 µmol, 1.20 eq) was added. After 5 min $POCl_3$ (52 μ L, 571 μ mol, 1.30 eq) was added dropwise and the reaction mixture was stirred for 30 min at 10 °C before it was allowed to warm up to rt. After 1 h the reaction mixture was heated to 80 °C and stirred for 16 h. The reaction mixture was carefully poured into saturated aqueous NaHCO₃-solution (5 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (10 mL), dried over Na2SO4 and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (n-pentane/EtOAc 10:1) to give compound 19g (97.3 mg, 395 μ mol, 90%) as pale yellow solid. R_f=0.45 (*n*-pentane/ EtOAc 10:1). ¹H-NMR (500 MHz, CDCl₃): $\delta = 9.26$ (s, 1H, CH_{arom}), 8.26 (s, 1H, CH_{arom}), 2.66 (s, 3H, SCH₃) ppm. ¹³C-NMR (126 MHz, CDCl₃): $\delta = 171.8$ (1 C, $C_{arom}SCH_3$), 159.9 (1 C, CH_{arom}), 148.7 (1 C, $C_{arom}CI$), 146.4 (1 C, C_{arom}), 136.4 (1 C, CH_{arom}), 136.0 (1 C, C_{arom}Cl), 135.9 (1 C, C_{arom}), 14.9 (1 C, SCH₃) ppm. FT-IR: neat; $\tilde{v} = 3041$ (m), 2929 (w), 2336 (w), 2047 (w), 1849 (w), 1585 (m), 1553 (w), 1529 (s), 1416 (s), 1370 (w), 1342 (w), 1302 (s), 1239 (w), 1191 (w), 1153 (m), 1120 (s), 983 (m), 965 (w), 918 (w), 803 (w), 733 (w), 705 (m), 651 (m), 620 (s), 527 (m), 475 (m) cm⁻¹. m.p.: 162 °C (CHCl₃). HRMS (APCl⁺): m/z calc. for C₈H₅Cl₂N₃S₁H₁ [M+H]⁺: 245.9654, found: 245.9650.

7-Chloro-6-fluoro-2-(methylthio)pyrido[3,2-d]pyrimidine (20a)



Compound 19g (20.8 mg, 85 µmol, 1.00 eq) was dissolved in DMSO (0.21 mL) before TBAF (1 m in THF, 211 µL, 211 µmol, 2.50 eq) was added dropwise. The yellow to greenish reaction mixture was stirred for 2 h at rt. It was poured into saturated aqueous NH₄Clsolution (5 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (npentane/EtOAc 10:1 to EtOAc) to give compound 20a (8.0 mg, 35 µmol, 41%) as colorless solid and the hydrolysis product pyridone **18e** (11.0 mg, 48 μmol, 57%). R_f=0.55 (*n*-pentane/EtOAc 10:1). ¹H-NMR (500 MHz, CDCl₃): δ = 9.20 (s, 1H, CH_{arom}), 8.31 (dd, J = 8.1, 0.8 Hz, 1H, CH_{arom}), 2.66 (s, 3H, SCH₃) ppm. ¹³C-NMR (126 MHz, CDCl₃): δ = 171.2 (d, J = 3.0 Hz, 1 C, C_{arom}SCH₃), 159.5 (d, J = 2.0 Hz, 1 C, CH_{arom}), 155.7 (d, J=246.6 Hz, 1 C, CF_{arom}), 146.7 (d, J=2.0 Hz 1 C, C_{arom}), 139.1 (d, J=4.0 Hz, 1 C, CH_{arom}), 133.5 (d, J=14.0 Hz, 1 C, C_{arom}), 125.8 (d, J=39.2 Hz, 1 C, CCl_{arom}) 14.8 (1 C, SCH₃) ppm. $^{19}\text{F-NMR}$ (283 MHz, CDCl₃): $\delta\!=\!-64.5$ (s, 1F, CF_{arom}) ppm. FT-IR: neat; \tilde{v} = 3054 (w), 3011 (w), 2929 (w), 2848 (w), 2687 (w), 228.2 (w), 2096 (w), 1859 (w), 1577 (m), 1540 (s), 1425 (s), 1377 (m), 1329 (m), 1305 (w), 1242 (m), 1184 (w), 1126 (m), 1035 (s), 962 (w), 928 (w), 850 (w), 758 (w), 718 (m), 666 (m), 631 (m), 573 (m), 538 (m) cm⁻¹. m.p.: 122 °C (CHCl₃). HRMS (APCl⁺): m/z calc. for C₈H₅Cl₁F₁N₃S₁H₁ [M + H]⁺: 229.9950, found: 229.9946.

7-Bromo-*N*-(2,4-dimethoxybenzyl)-2-(methylthio)pyrido[3,2-*d*] pyrimi-din-6-amine (19 h)



Pyridone 18f (400 mg, 1.47 mmol, 1.00 eg) and PyBroP (891 mg, 1.91 mmol, 1.30 eq) were suspended in THF (14.0 mL) and DBU (331 µL, 2.21 mmol, 1.50 eq) was added dropwise at rt. The resulting solution was stirred for 10 min before 2,4-dimethoxybenzylamine (663 $\,\mu\text{L},\,$ 4.41 mmol, 3.00 eq) was added. The reaction mixture was heated to 60 °C for 22 h before it was poured into saturated aqueous NH₄Cl-solution (20 mL) and extracted with EtOAc (3×30 mL). The combined organic layers were washed with brine (30 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (n-pentane/EtOAc 7:1 to 1:1) to give compound **19h** (349 mg, 828 µmol, 56%) as orange solid. R_f=0.32 (*n*-pentane/EtOAc 5:1). ¹H-NMR (500 MHz, CDCl₃): $\delta = 9.02$ (d, J =0.7 Hz 1H, CH_{hetarom}), 8.12 (d, J=0.8 Hz, 1H, CH_{hetarom}), 7.32 (d, J=8.3 Hz, 1H, CH_{arom}), 6.51 (d, J = 2.7 Hz, 1H, CH_{arom}), 6.45 (dd, J = 8.3 Hz, 2.5 Hz, 1H, CH_{arom}), 6.11 (t, J=5.4 Hz, 1H, NH), 4.71 (d, J=5.6 Hz, 2H, CH₂), 3.88 (s, 3H, OCH₃), 3.80 (s, 3H, OCH₃), 2.63 (s, 3H, SCH₃) ppm. ¹³C-NMR (126 MHz, CDCl₃): δ = 164.9 (1 C, C_{hetarom} SCH₃), 160.8 (1 C, C_{arom}), 159.0 (1 C, C_{arom}), 157.8 (1 C, $CH_{hetarom}$), 152.6 (1 C, $C_{hetarom}$), 144.1 (1 C, $C_{hetarom}$), 137.8 (1 C, $CH_{hetarom}$), 136.9 (1 C, $C_{hetarom}$), 130.9 (1 C, CH_{arom}), 118.9 (1 C, C_{arom}), 117.2 (1 C, C_{hetarom}), 104.1 (1 C, CH_{arom}), 99.0 (1 C, CH_{arom}), 55.6 (1 C, CH_3), 55.6 (1 C, CH_3), 41.7 (1 C, CH_2), 14.6 (1 C, SCH₃) ppm. FT-IR: neat; $\tilde{v} = 3263$ (w), 3000 (w), 2952 (w), 2924 (m), 2830 (w), 2103 (w), 1671 (w), 1589 (w), 1560 (m), 1503 (s), 1451 (w), 1420 (w), 1391 (m), 1353 (w), 1333 (m), 1311 (w), 1285 (w), 1258 (m), 1208 (m), 1180 (w), 1154 (w), 1125 (s), 1044 (w), 1028 (m), 1011 (w), 955 (m), 922 (w), 894 (w), 830 (m), 812 (w), 763 (w), 730 (w), 643 (m), 595 (m), 536 (m), 468 (w), 425 (w) cm⁻¹. m.p.: 142 °C (EtOAc). HRMS (ESI⁺): m/z calc. for $C_{17}H_{18}Br_1N_4O_2S_1$ [M+H]⁺: 421.0328 & 423.0309, found: 421.0340 & 423.0320.

7-Chloro-*N*-(4-methoxybenzyl)-2-(methylthio)pyrido[3,2-*d*] pyrimidin-6-amine (19 i)



Pyridone 18e (100 mg, 439 µmol, 1.00 eq) and PyBroP (266 mg, 571 µmol, 1.30 eq) were suspended in THF (3.50 mL) and DBU (165 µL, 1.10 mmol, 2.50 eq) was added dropwise at rt. The resulting solution was stirred for 10 min before 4-methoxybenzylamine (172 μ L, 1.32 mmol, 3.00 eq) was added. The reaction mixture was heated to 65°C for 20 h before it was poured into saturated aqueous NH₄Cl-solution (15 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were washed with brine (20 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (n-pentane/EtOAc 5:1 to 3:1) to give compound 19i (103 mg, 297 µmol, 68%) as yellow solid. R_f=0.45 (*n*-pentane/ EtOAc 5:1). ¹H-NMR (500 MHz, CDCl₃): $\delta = 9.02$ (d, J = 0.6 Hz, 1H, $CH_{hetarom}$), 7.96 (d, J=0.7 Hz, 1H, $CH_{hetarom}$), 7.36–7.33 (m, 2H, 2× CH_{arom}), 6.92–6.89 (m, 2H, 2×CH_{arom}), 5.75 (t, J=5.1 Hz, 1H, NH), 4.72 (d, J=5.5 Hz, 2H, CH₂), 3.81 (s, 3H, OCH₃), 2.63 (s, 3H, SCH₃) ppm. $^{13}\text{C-NMR}$ (126 MHz, CDCl_3): $\delta\!=\!165.2$ (1 C, $C_{\text{hetarom}}\text{SCH}_3$), 159.3 (1 C, Carom), 157.6 (1 C, CH_{hetarom}), 151.9 (1 C, C_{hetarom}), 144.1 (1 C, C_{hetarom}), 136.4 (1 C, C_{hetarom}), 133.9 (1 C, CH_{hetarom}), 130.3 (1 C, C_{arom}), 129.5 (2 C, $2\times CH_{arom}),\ 125.9\ (1\ C,\ C_{hetarom}),\ 114.3\ (2\ C,\ 2\times CH_{arom}),\ 55.5\ (1\ C,\ OCH_3),\ 45.5\ (1\ C,\ CH_2),\ 14.7\ (1\ C,\ SCH_3)\ ppm.\ FT-IR:\ neat;\ \tilde{\nu}=3431\ (w),\ 3029\ (w),\ 2947\ (w),\ 2926\ (w),\ 2900\ (w),\ 2828\ (w),\ 2166\ (w),\ 2056\ (w),\ 1879\ (w),\ 1684\ (w),\ 1602\ (m),\ 1563\ (m),\ 1543\ (w),\ 1502\ (s),\ 1465\ (w),\ 1391\ (m),\ 1339\ (w),\ 1287\ (m),\ 1243\ (s),\ 1224\ (w),\ 1185\ (w),\ 1135\ (w),\ 1135\ (w),\ 1036\ (m),\ 1030\ (s),\ 987\ (w),\ 950\ (w),\ 926\ (m),\ 900\ (w),\ 879\ (w),\ 840\ (w),\ 814\ (s),\ 791\ (w),\ 761\ (w),\ 730\ (m),\ 711\ (w),\ 667\ (w),\ 643\ (w),\ 624\ (w),\ 579\ (m),\ 516\ (w),\ 478\ (w)\ cm^{-1}.\ m.p.:\ 114\ ^C\ (EtOAc).\ HRMS\ (ESI^+):\ m/z\ calc.\ for\ C_{16}H_{16}Cl_1N_4O_1S_1\ [M+H]^+:\ 347.0728,\ found:\ 347.0737.$

7-Chloro-*N*-(2,4-dimethoxybenzyl)-2-(methylthio)pyrido[3,2-*d*] pyrimidin-6-amine (19j)



Pyridone 18e (200 mg, 878 umol, 1.00 eg) and PyBroP (532 mg, 1.14 mmol, 1.30 eq) were suspended in THF (7.00 mL) and DBU (198 µL, 1.32 mmol, 1.50 eq) was added dropwise at rt. The resulting solution was stirred for 10 min before 2,4-dimethoxybenzylamine (396 µL, 2.64 mmol, 3.00 eq) was added. The reaction mixture was heated to 60 °C for 22 h before it was poured into saturated aqueous NH₄Cl-solution (10 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were washed with brine (20 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (n-pentane/EtOAc 5:1 to 1:1) to give compound **19j** (330 mg, 876 µmol, 99%) as orange solid. R_f=0.30 (*n*-pentane/EtOAc 5:1). ¹H-NMR (500 MHz, CDCl₃): δ = 9.05 (s, 1H, CH_{hetarom}), 7.92 (d, J=0.6 Hz, 1H, CH_{hetarom}), 7.34 (d, J=8.2 Hz, 1H, CH_{arom}), 6.50 (d, J=2.4 Hz, 1H, CH_{arom}), 6.45 (dd, J=8.2 Hz, 2.4 Hz, 1H, CH_{arom}), 6.07 (t, J=5.6 Hz, 1H, NH), 4.73 (d, J=5.6 Hz, 2H, CH₂), 3.88 (s, 3H, OCH₃), 3.80 (s, 3H, OCH₃), 2.63 (s, 3H, SCH₃) ppm. ¹³C-NMR (126 MHz, CDCl₃): δ = 164.9 (1 C, C_{hetarom}SCH₃), 160.8 (1 C, C_{arom}), 159.0 (1 C, C_{arom}), 157.4 (1 C, CH_{hetarom}), 152.1 (1 C, C_{hetarom}), 144.0 (1 C, C_{hetarom}), 136.3 (1 C, C_{hetarom}), 133.8 (1 C, CH_{hetarom}), 131.0 (1 C, CH_{arom}), 126.3 (1 C, C_{hetarom}), 118.7 (1 C, C_{arom}), 104.0 (1 C, CH_{arom}), 98.9 (1 C, CH_{arom}), 55.6 (1 C, CH₃), 55.6 (1 C, CH₃), 41.4 (1 C, CH₂), 14.7 (1 C, SCH₃) ppm. FT-IR: neat; $\tilde{v} = 3248$ (w), 3073 (w), 3001 (w), 2954 (w), 2926 (w), 2830 (w), 1604 (m), 1562 (s), 1521 (w), 1504 (m), 1452 (w), 1423 (w), 1394 (s), 1354 (w), 1336 (m), 1314 (w), 1286 (w), 1260 (m), 1210 (m), 1181 (w), 1156 (w), 1139 (w), 1126 (s), 1046 (w), 1024 (m), 968 (m), 942 (w), 922 (w), 890 (m), 853 (w), 832 (m), 811 (w), 764 (w), 734 (w), 647 (w), 627 (w), 608 (m), 584 (w), 540 (m), 471 (w), 432 (w) cm⁻¹. m.p.: 149 °C (EtOAc). HRMS (ESI⁺): m/z calc. for $C_{17}H_{18}CI_1N_4O_2S_1$ [M + H]⁺: 377.0834, found: 377.0841.

7-Chloro-2-(methylthio)pyrido[3,2-d]pyrimidin-6-amine (20b)



Pyridine **19j** (43.0 mg, 114 µmol, 1.00 eq) was suspended in CH_2CI_2 (0.25 mL) and cooled to 0 °C. TFA (0.75 mL, 9.74 mmol, 85.0 eq) was added dropwise and the resulting solution was stirred for 2.5 h. The intense red reaction mixture was poured into saturated aqueous NaHCO₃-solution (10 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (*n*-pentane/EtOAc 2:1 to 1:1) to give compound



20b (16.0 mg, 71 µmol, 62%) as beige solid. R_r =0.33 (*n*-pentane/ EtOAc 2:1). ¹H-NMR (500 MHz, CDCl₃): δ =8.97 (s, 1H, CH_{arom}), 8.03 (s, 1H, CH_{arom}), 5.47 (s, 2H, NH₂), 2.63 (s, 3H, SCH₃) ppm. ¹³C-NMR (126 MHz, CDCl₃): δ =166.2 (1 C, C_{arom}SCH₃), 157.4 (1 C, CH_{arom}), 153.4 (1 C, C_{arom}NH₂), 144.3 (1 C, C_{arom}), 135.9 (1 C, C_{arom}), 134.9 (1 C, CH_{arom}), 125.3 (1 C, C_{arom}Cl), 14.7 (1 C, SCH₃) ppm. FT-IR: neat; $\tilde{\nu}$ = 3427 (w), 3305 (w), 3249 (w), 3146 (m), 2925 (w), 1732 (w), 1645 (m), 1554 (m), 1473 (m), 1425 (w), 1395 (m), 1340 (w), 1308 (w), 1237 (w), 670 (w), 637 (w), 618 (m), 576 (w), 475 (w), 430 (w) cm⁻¹. m.p.: 196°C (EtOAc). HRMS (ESI⁺): *m/z* calc. for C₈H₇Cl₁N₄S₁H₁ [M + H]⁺: 227.0153, found: 227.0159.

O-Benzyl-*N*-(7-chloro-2-(methylthio)pyrido[3,2-*d*] pyrimidin-6-yl)hydroxylamine (20 c)



Pyridone 18e (100 mg, 439 µmol, 1.00 eq) and PyBroP (266 mg, 571 µmol, 1.30 eq) were suspended in THF (4.00 mL) and DBU (198 µL, 1.32 mmol, 3.00 eq) was added dropwise at rt. The resulting solution was stirred for 10 min before tert-butyl (benzyloxy) carbamate (294 mg, 1.32 mmol, 3.00 eg) was added. The reaction mixture was stirred for 30 min and heated to 60°C for 20 h before it was poured into saturated aqueous NH₄Cl-solution (15 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were washed with brine (20 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was dissolved in CH₂Cl₂ (7.00 mL), cooled to 0 °C and TFA (4.42 mL, 57.7 mmol, 132 eq) was added dropwise. After 30 min the reaction mixture was allowed to warm to r.t. and was stirred for additional 1 h before it was poured into saturated aqueous NaHCO₃-solution (20 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were washed with brine (20 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (n-pentane/EtOAc 10:1 to 5:1) to give compound 20c (96.0 mg, 289 µmol, 66%) as yellow solid over two steps. It was isolated as a 5:1 mixture with amidine-like pyridone tautomer. The equilibrium between both could be changed by the addition of different acids. NMR analytics are given for the main tautomer **20 c**. $R_f = 0.38$ (*n*-pentane/EtOAc 5:1). ¹H-NMR (300 MHz, CDCl₃): δ = 8.24 (s, 1H, CH_{hetarom}), 8.01 (s, 1H, NH), 7.48-7.35 (m, 5H, 5×CH_{arom}), 7.28 (d, J=0.6 Hz, 1H, CH_{hetarom}), 5.20 (s, 2H, CH₂), 2.55 (s, 3H, SCH₃) ppm. ¹³C-NMR (75 MHz, CDCl₃): $\delta\!=\!$ 164.9 (1 C, $\mathit{C}_{\text{hetarom}}\text{SCH}_3$), 144.4 (1 C, $\mathit{C}_{\text{hetarom}}$), 143.3 (1 C, $\mathit{C}_{\text{hetarom}}$), 142.3 (1 C, CH_{hetarom}), 133.1 (1 C, C_{hetarom}), 130.0 (1 C, CH_{hetarom}), 129.4 (2 C, 2×CH_{arom}), 129.2 (1 C, C_{arom}), 128.7 (2 C, 2×CH_{arom}), 128.6 (1 C, C_{arom}), 127.9 (1 C, C_{hetarom}), 77.2 (1 C, CH₂), 14.5 (1 C, SCH₃) ppm. FT-IR: neat; $\tilde{v} = 3240$ (w), 3147 (w), 3032 (w), 2925 (w), 2872 (w), 1617 (w), 1590 (m), 1567 (w), 1537 (w), 1446 (m), 1388 (s), 1317 (w), 1221 (w), 1186 (s), 1155 (w), 1082 (w), 1043 (s), 1020 (w), 945 (m), 884 (w), 836 (w), 778 (w), 745 (m), 693 (s), 670 (w), 643 (m), 587 (w), 551 (w), 491 (w), 443 (w) cm⁻¹. m.p.: 159°C (EtOAc). HRMS (ESI⁺): *m/z* calc. for C₁₅H₁₄Cl₁N₄O₁S₁ [M + H]⁺: 333.0577, found: 333.0571.

*N*6,*N*7-Bis(2,4-dimethoxybenzyl)-2-(methylthio)pyrido[3,2-*d*] pyrimidine-6,7-diamine (21)



Pyridine **19**j (25.0 mg, 66.3 μmol, 1.00 eg), Pd₂(dba)₃ (2.2 mg, 7 µmol, 0.04 eq), XPhos (3.8 mg, 8 µmol, 0.12 eq) and NaO^tBu (7.5 mg, 80 µmol, 1.20 eg) were suspended in ^tBuOH (0.30 mL). 2,4dimethoxybenzylamine (11 µL, 69.7 mmol, 1.05 eq) was added and the resulting suspension was heated to 95 °C for 22 h. The intense red reaction mixture was poured into saturated aqueous NH₄Clsolution (5 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (npentane/EtOAc 2:1 to 1:1) to give compound 21 (22.6 mg, 45 μ mol, 68%) as orange oil. R_f=0.55 (*n*-pentane/EtOAc 1:1). ¹H-NMR (500 MHz, CDCl₃): δ = 8.83 (s, 1H, CH_{hetarom}), 7.32 (d, J=8.1 Hz, 1H, CH_{arom}), 7.14 (d, J=8.4 Hz, 1H, CH_{arom}), 6.89 (s, 1H, CH_{hetarom}), 6.45-6.39 (m, 4H, 4×CH_{arom}), 5.11 (s, 1H, NH), 4.65 (d, J=4.9 Hz, 2H, CH₂), 4.54 (s, 1H, NH), 4.30 (d, J=5.0 Hz, 2H, CH₂), 3.78-3.77 (m, 12H, $4 \times OCH_3$, 2.63 (s, 3H, SCH₃) ppm. ¹³C-NMR (75 MHz, CDCl₃): $\delta = 164.3$ (1 C, C_{hetarom}SCH₃), 160.9 (1 C, C_{arom}), 160.7 (1 C, C_{arom}), 158.9 (1 C, Carom), 158.7 (1 C, Carom), 154.9 (1 C, CH_{betarom}), 149.7 (1 C, C_{betarom}), 147.8 (1 C, C_{hetarom}), 139.9 (1 C, C_{hetarom}), 131.4 (1 C, CH_{arom}), 131.2 (1 C, C_{hetarom}), 130.6 (1 C, CH_{arom}), 119.3 (1 C, C_{arom}), 117.5 (1 C, C_{arom}), 107.3 $(1 \text{ C}, \text{ CH}_{hetarom}), 104.3 (1 \text{ C}, \text{ CH}_{arom}), 104.1 (1 \text{ C}, \text{ CH}_{arom}), 98.9 (1 \text{ C}, \text{ CH}_{arom}), 104.1 (1 \text{ C}, \text{ CH}_{arom}),$ CH_{arom}), 98.8 (1 C, CH_{arom}), 55.5 (1 C, OCH_{3}), 55.5 (1 C, OCH_{3}), 55.5 (2 C, 2×OCH₃), 43.3 (1 C, CH₂), 41.7 (1 C, CH₂), 14.6 (1 C, SCH₃) ppm. FT-IR: neat; $\tilde{v} = 3345$ (w), 2931 (w), 2838 (w), 2251 (w), 1613 (w), 1588 (w), 1559 (w), 1507 (m), 1489 (w), 1463 (w), 1438 (w), 1400 (w), 1375 (w), 1288 (w), 1254 (w), 1207 (m), 1156 (m), 1129 (w), 1036 (m), 904 (s), 836 (w), 791 (w), 724 (s), 647 (w), 588 (w), 509 (w), 464 (w). HRMS (ESI⁺): m/z calc. for $C_{26}H_{30}N_5O_4S_1$ [M+H]⁺: 508.2013, found: 508.2019.

7-((2,4-Dimethoxybenzyl)amino)-2-(methylthio)pyrido[3,2-*d*] pyrimidin-6(5*H*)-one (22)



Pyridone **18f** (74.4 mg, 272 μmol, 1.00 eq), benzylamine (44 μL, 286 µmol, 1.05 eq), Pd₂dba₃ (10.0 mg, 11 µmol, 0.04 eq), XPhos (15.6 mg, 33 µmol, 0.12 eq) and NaO^tBu (57.5 mg, 598 µmol, 2.20 eq) were suspended in 'BuOH (1.00 mL) and heated to 95 °C for 22 h. The greenish reaction mixture was filtered over a pad of celite which was rinsed with EtOAc/MeOH (10:1, 10.0 mL) and all solvents were evaporated from the filtrate under reduced pressure. The crude product was purified by column chromatography on silica (n-pentane/EtOAc 1:1 to EtOAc) to give compound 22 (73.0 mg, 204 µmol, 75%) as yellow solid. R_f=0.51 (EtOAc). ¹H-NMR (500 MHz, DMSO-d6): $\delta = 12.10$ (s, 1H, NCOH_{hetarom}), 8.31 (s, 1H, CH_{hetarom}), 7.28 (t, J=6.3 Hz, 1H, NH), 7.09 (d, J=8.5 Hz, 1H, CH_{arom}), 6.60 (d, J=2.5 Hz, 1H, CH_{arom}), 6.47 (dd, J=8.2, 2.3 Hz, 1H, CH_{arom}), 6.24 (s, 1H, CH_{hetarom}), 4.35 (d, J=6.2 Hz, 2H, CH₂), 3.86 (s, 3H, OCH₃), 3.73 (s, 3H, OCH₃), 2.46 (s, 3H, SCH₃) ppm. ¹³C-NMR (126 MHz, DMSO-d6): $\delta = 163.4$ (1 C, $C_{hetarom}SCH_3$), 159.9 (1 C, C_{arom}), 157.8 (1 C, C_{arom}), 156.3 (1 C, C_{hetarom}), 145.9 (1 C, C_{hetarom}), 144.7 (1 C, NC_{hetarom}O),



142.0 (1 C, $CH_{hetarom}$), 128.5 (1 C, CH_{arom}), 121.8 (1 C, $C_{hetarom}$), 116.9 (1 C, C_{arom}), 104.6 (1 C, CH_{arom}), 99.5 (1 C, $CH_{hetarom}$), 98.4 (1 C, CH_{arom}), 55.5 (1 C, OCH_3), 55.1 (1 C, OCH_3), 39.9 (1 C, CH_2), 13.6 (1 C, SCH_3) ppm. FT-IR: neat; $\tilde{\nu} = 3371$ (w), 3126 (w), 2993 (w), 2923 (w), 2832 (m), 2749 (w), 1659 (s), 1587 (s), 1562 (w), 1503 (m), 1456 (m), 1417 (w), 1373 (s), 1288 (m), 1262 (w), 1204 (m), 1158 (m), 1133 (w), 1065 (w), 1034 (m), 973 (w), 926 (w), 890 (w), 857 (w), 828 (m), 770 (w), 752 (w), 720 (w), 669 (w), 634 (w), 608 (w), 589 (w), 537 (m), 451 (m), 414 (w) cm⁻¹. m.p.: 232°C (EtOAc). HRMS (ESI⁺): m/z calc. for $C_{17}H_{19}N_4O_3S_1$ [M+H]⁺: 359.1172, found: 359.1168.

N-(2,4-Dimethoxybenzyl)-6-methylpyrido[3,2-*d*] pyrimidin-7-amine (23)



Pyridopyrimidine **18c** (20.0 mg, 89 µmol, 1.00 eg), Pd₂dba₃ (3.3 mg, 4 µmol, 0.04 eg), XantPhos (6.2 mg, 11 µmol, 0.12 eg) and Cs₂CO₃ (40.7 mg, 125 µmol, 1.40 eq) were suspended in toluene (0.50 mL) and benzylamine (16.4 µL, 107 µmol, 1.20 eq) was added before the reaction mixture was heated to 110°C for 14 h. The greenish reaction mixture was poured into saturated aqueous NaHCO₃solution (5 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (EtOAc to EtOAc/MeOH 10:1) to give compound 23 (27.6 mg, 89 µmol, 99%) as pale yellow solid. $R_f = 0.26$ (EtOAc). ¹H-NMR (500 MHz, $CDCl_3$): $\delta = 9.21$ (s, 1H, $CH_{hetarom}$), 9.09 (s, 1H, $CH_{hetarom}$), 7.23 (d, J =8.2 Hz, 1H, CH_{arom}), 7.13 (s, 1H, CH_{hetarom}), 6.51 (d, J=2.2 Hz, 1H, CH_{arom}), 6.46 (dd, J = 8.3, 2.2 Hz, 1H, CH_{arom}), 4.94 (t, J = 5.6 Hz, 1H, NH), 4.43 (d, J=5.5 Hz, 2H, CH₂), 3.87 (s, 3H, OCH₃), 3.81 (s, 3H, OCH₃), 2.61 (s, 3H, CH₃) ppm. ¹³C-NMR (126 MHz, CDCl₃): δ = 161.1 (1 C, C_{arom}), 158.8 (1 C, C_{arom}), 158.0 (1 C, CH_{hetarom}), 155.3 (1 C, CH_{hetarom}), 152.3 (1 C, C_{hetarom}), 148.9 (1 C, C_{hetarom}), 146.7 (1 C, C_{hetarom}), 132.9 (1 C, C_{hetarom}), 130.4 (1 C, CH_{arom}), 117.1 (1 C, C_{arom}), 106.6 (1 C, CH_{hetarom}), 104.2 (1 C, CH_{arom}), 99.1 (1 C, CH_{arom}), 55.6 (2 C, 2×OCH₃), 43.3 (1 C, CH₂), 21.6 (1 C, CH₃) ppm. FT-IR: neat; $\tilde{v} = 3272$ (m), 3050 (w), 3001 (w), 2942 (w), 2840 (w), 2366 (w), 2202 (w), 2176 (w), 2136 (w), 2058 (w), 2009 (w), 1945 (w), 1719 (w), 1611 (w), 1579 (m), 1530 (s), 1503 (w), 1454 (w), 1431 (m), 1414 (w), 1375 (w), 1354 (m), 1301 (m), 1258 (w), 1230 (w), 1208 (s), 1152 (m), 1124 (m), 1091 (w), 1061 (w), 1034 (m), 995 (w), 920 (m), 844 (m), 827 (w), 795 (w), 760 (w), 743 (w), 712 (m), 688 (w), 636 (w), 615 (m), 580 (s), 544 (w) cm⁻¹. m.p.: 148 °C (EtOAc). HRMS (ESI⁺): m/z calc. for $C_{17}H_{18}N_4O_2H_1$ [M+ H]⁺: 311.1503, found: 311.1503.

7-Amino-2-(methylthio)pyrido[3,2-*d*] pyrimidine-6-carbaldehyde (24)



Pyridopyrimidine **18g** (20.0 mg, 74 μ mol, 1.00 eq) was suspended in 1,4-dioxane (0.50 mL) and SeO₂ (9.9 mg, 89 μ mol, 1.20 eq) was added. The suspension was stirred for 56 h at 100 °C before it was poured into saturated aqueous NH₄Cl-solution (5 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (*n*-pentane/EtOAc 10:1 to 5:1) to give compound **24** (16.0 mg, 56 mmol, 76%) as yellow solid. R_f =0.09 (*n*-pentane/EtOAc 10:1). ¹H-NMR (500 MHz, CDCl₃): δ =10.30 (s, 1H, CHO), 9.46 (d, J=0.8 Hz, 1H, CH_{arom}), 8.51 (t, J=0.8 Hz, 1H, CH_{arom}), 2.70 (s, 3H, SCH₃) ppm. ¹³C-NMR (126 MHz, CDCl₃): δ =189.6 (1 C, CHO), 174.4 (1 C, C_{arom}SCH₃), 162.1 (1 C, CH_{arom}), 147.8 (1 C, NC_{arom}CHO), 147.3 (1 C, C_{arom}), 140.5 (1 C, CH_{arom}), 136.7 (1 C, C_{arom}), 123.6 (1 C, CBr_{arom}), 15.0 (1 C, SCH₃) ppm. FT-IR: neat; \tilde{v} =3037 (m), 2925 (w), 2828 (w), 2554 (w), 2372 (w), 2220 (w), 2149 (w), 2050 (w), 1717 (s), 1581 (s), 1550 (w), 1527 (w), 1420 (w), 1397 (m), 1358 (m), 1338 (w), 1298 (w), 1240 (m), 1179 (w), 1127 (s), 985 (s), 926 (w), 809 (w), 779 (s), 734 (w), 711 (w), 694 (w), 631 (m), 597 (w), 481 (w), 448 (m), 428 (w) cm⁻¹. m.p.: 153 °C (EtOAc). HRMS (APCI⁺): *m/z* calc. for C₉H₆Br₁N₃O₁S₁H₁ [M+H]⁺: 285.9467 & 283.9488, found: 285.9469 & 283.9489.

Methyl 2-(6,7-dichloro-2-(methylthio)-5,8-dihydropyrido [3,2-d]pyrimi-din-8-yl)acetate (25)



Pyridine 19g (25.0 mg, 102 µmol, 1.00 eg) was dissolved in THF (0.55 mL) and Reformatsky-reagent (1 m in THF, 152 µL, 152 µmol, 1.50 eq) was added at rt. After 1 h the reaction mixture was poured into saturated aqueous NH₄Cl-solution (5 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (5 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (n-pentane/EtOAc 5:1 to 2:1) to give compound 25 (33.0 mg, 102 μ mol, 99%) as colorless solid R_f=0.07 (n-pentane/EtOAc 5:1). ¹H-NMR (500 MHz, CDCl₃): δ = 7.41 (s, 1H, CH_{arom}), 6.10 (s, 1H, NH), 5.04 (dd, J=10.8, 2.4 Hz, 1H, CH), 3.74 (s, 3H, CO₂CH₃), 3.00 (dd, J=17.5, 2.5 Hz, 1H, CH_aH_bCO₂CH₃), 2.80 (dd, J=17.5, 10.8 Hz, 1H, CH₂H_bCO₂CH₃), 2.49 (s, 3H, SCH₃) ppm. ¹³C-NMR (126 MHz, CDCl₃): $\delta = 172.2$ (1 C, CO₂CH₃), 160.1 (1 C, C_{arom}SCH₃), 142.3 (1 C, C_{olef}Cl), 141.5 (1 C, C_{arom}), 138.9 (1 C, C_{olef}Cl), 132.9 (1 C, CH_{arom}), 130.0 (1 C, C_{arom}), 52.4 (1 C, CO₂CH₃), 52.2 (1 C, CHCH₂), 40.8 (1 C, $CH_2CO_2CH_3$), 13.8 (1 C, SCH_3) ppm. FT-IR: neat; $\tilde{v} = 3325$ (w), 2954 (w), 2927 (w), 2851 (w), 1723 (w), 1591 (w), 1542 (w), 1498 (w), 1435 (w), 1405 (w), 1380 (w), 1316 (w), 1287 (w), 1244 (w), 1225 (w), 1194 (w), 1172 (w), 1148 (w), 1034 (w), 980 (w), 952 (w), 892 (w), 802 (w), 748 (w), 712 (w), 666 (w), 633 (w), 575 (w), 540 (w), 460 (w), 424 (w) cm⁻¹. m.p.: 144 °C (EtOAc). HRMS (ESI⁺): m/z calc. for C₁₁H₁₁Cl₂N₃O₂S₁H₁ [M + H]⁺: 320.0022 & 321.9993, found: 320.0024 & 321.9993.

6,7-Dichloro-2-(methylsulfonyl)pyrido[3,2-d]pyrimidine (26)



Pyridine **19 g** (144 mg, 585 μ mol, 1.00 eq) was suspended in MeCN (0.91 mL), CCl₄ (0.91 mL) and H₂O (1.82 mL) before RuCl₃ • x H₂O (12.1 mg, 59 μ mol, 0.10 eq) and NalO₄ (563 mg, 2.63 mmol, 4.50 eq) was added. The resulting deep brown biphasic reaction mixture was stirred for 75 min at rt. It was then poured into brine (10 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (*n*-pentane/EtOAc 3:2 to 1:1) to give

www.eurjoc.org



compound **26** (150 mg, 539 µmol, 92%) as colorless solid. R_f =0.29 (*n*-pentane/EtOAc 2:1). ¹H-NMR (500 MHz, CDCl₃): δ =9.70 (d, J= 0.9 Hz, 1H, CH_{arom}), 8.62 (d, J=0.9 Hz, 1H, CH_{arom}), 3.47 (s, 3H, SO₂CH₃) ppm. ¹³C-NMR (126 MHz, CDCl₃): δ =163.5 (1 C, C_{arom}SO₂CH₃), 162.5 (1 C, CH_{arom}), 154.2 (1 C, CCl_{arom}), 145.9 (1 C, C_{arom}), 138.3 (1 C, C_{arom}), 138.1 (1 C, CCl_{arom}), 137.9 (1 C, CH_{arom}), 39.6 (1 C, SO₂CH₃) ppm. FT-IR: neat; $\tilde{\nu}$ =3070 (w), 3038 (w), 2929 (w), 2323 (w), 2124 (w), 1729 (w), 1582 (w), 1560 (w), 1543 (w), 1431 (m), 1410 (w), 1371 (w), 1303 (s), 1195 (w), 1150 (w), 1123 (s), 984 (w), 961 (m), 920 (m), 806 (w), 765 (s), 710 (w), 650 (w), 616 (m), 548 (m), 526 (m), 491 (s), 440 (w), 420 (w) cm⁻¹. m.p.: 185°C (CH₂Cl₂). HRMS (ESI⁺): *m/z* calc. for C₈H₅Cl₂N₃O₂S₁Na₁ [M+Na]⁺: 299.9372 & 301.9342, found: 299.9367 & 301.3993.

7-Aminopyrido[3,2-*d*]pyrimidin-6(5*H*)-one 2,2,2-trifluoroacetate (27 a)



Pyridopyrimidine 18b (41.0 mg, 156 µmol, 1.00 eq) was suspended in CHCl3 (3.00 mL) and cooled to 0 $^\circ\text{C}$ before TFA (608 $\mu\text{L},$ 7.82 mmol, 50.0 eq) was added dropwise. The solution was stirred for 15 min before it was allowed to warm to rt and stirred for additional 8 h. All solvents were evaporated under reduced pressure and the crude product was purified by column chromatography on silica (CHCl₃/MeOH 8:1 to 7:1) to give TFA salt of compound 27 a (41.0 mg, 149 µmol, 95%) as brown solid. R_f=0.27 (CHCl₃/MeOH 7:1). ¹H-NMR (500 MHz, DMSO-d6): δ = 12.12 (s, 1H, NH), 8.67 (s, 1H, CH_{arom}), 8.44 (s, 1H, CH_{arom}), 6.66 (s, 2H, NH₂), 6.65 (s, 1H, CH_{arom}) ppm. ¹³C-NMR (126 MHz, CDCl₃): δ = 157.7 (q, J = 30.9 Hz, 1 C, $COCF_3$), 156.8 (1 C, C_{arom}), 152.2 (1 C, CH_{arom}), 146.0 (1 C, NHCO), 145.1 (1 C, C_{arom}), 141.1 (1 C, CH_{arom}), 125.2 (1 C, C_{arom}), 117.3 (q, J = 291.5 Hz, 1 C, CF_3), 102.6 (1 C, CH_{arom}) ppm. ¹⁹F-NMR (283) MHz, CDCl₃): $\delta = -75.8$ (s, 3F, CF₃), -164.9 (s, 6F, internal standard C_6F_6) ppm. FT-IR: neat; $\tilde{v} = 3398$ (m), 3276 (w), 3138 (w), 3006 (w), 2939 (w), 2833 (w), 2765 (w), 2702 (w), 2164 (w), 2018 (w), 1940 (w), 1897 (w), 1674 (m), 1626 (w), 1577 (s), 1503 (w), 1467 (m), 1406 (w), 1366 (m), 1316 (w), 1286 (w), 1193 (m), 1143 (s), 953 (m), 925 (w), 898 (w), 846 (m), 800 (m), 772 (w), 720 (m), 631 (w), 606 (w), 588 (w) cm⁻¹. m.p.: 269 °C decomposition (MeOH). HRMS (ESI⁺): m/z calc. for $C_7H_6N_4O_1H_1$ [M + H]⁺: 163.0614, found: 163.0615.

7-Amino-2-(methylthio)pyrido[3,2-*d*]pyrimidin-6(5*H*)-one 2,2,2-tri-fluoroacetate (27 b)



Pyridopyrimidine **18d** (38.0 mg, 120 μmol, 1.00 eq) was suspended in CHCl₃ (2.50 mL) and cooled to 0 °C before TFA (480 μL, 6.16 mmol, 50.0 eq) was added dropwise. The solution was stirred for 15 min before it was allowed to warm to rt and stirred for additional 18 h. All solvents were evaporated under reduced pressure and the crude product was purified by column chromatography on silica (EtOAc/MeOH 20:1 to 10:1) to give TFA salt of compound **27 b** (41.0 mg, 120 μmol, 99%) as brownish solid. If the reaction was scaled up to 1.88 mmol the yield dropped to 70%. R_f =0.41 (EtOAc). ¹H-NMR (500 MHz, DMSO-d6): δ =12.04 (s, 1H, NHCO), 8.29 (s, 1H, CH_{arom}), 6.76 (s, 2H, NH₂), 6.54 (s, 1H, CH_{arom}), 2.48 (s, 3H, SCH₃) ppm. ¹³C-NMR (126 MHz, CDCl₃): δ =163.2 (1 C, C_{arom} SCH₃), 157.7 (q, J=30.9 Hz, 1 C, CF₃CO₂H), 156.4 (1 C, CONH), 146.6 (1 C, C_{arom}), 146.1 (1 C, C_{arom}), 141.8 (1 C, CH_{arom}), 122.3 (1 C, C_{arom}), 117.4 (q, J = 304.1 Hz, 1 C, CF_3), 102.0 (1 C, CH_{arom}), 13.7 (1 C, SCH₃) ppm. ¹⁹F-NMR (283 MHz, CDCI₃): δ = -75.8 (s, 3F, CF_3), -164.9 (s, 6F, internal standard C_6F_6) ppm. FT-IR: neat; $\tilde{\nu}$ = 3437 (w), 3328 (m), 3150 (w), 2926 (w), 2882 (w), 2437 (w), 1665 (m), 1605 (w), 1564 (s), 1445 (m), 1359 (s), 1314 (w), 1272 (w), 1244 (w), 1198 (w), 1173 (w), 1134 (s), 942 (w), 870 (w), 844 (m), 801 (m), 769 (w), 724 (m), 654 (w), 600 (w), 563 (w), 534 (m), 461 (w), 428 (w) cm⁻¹. m.p.: 251 °C decomposition (MeOH). HRMS (ESI⁺): *m/z* calc. for $C_8H_8N_4O_1S_1H_1$ [M + H]⁺: 209.0492, found: 209.0491.

7-((6-Methylpyrido[3,2-*d*]pyrimidin-7-yl)amino)pyrido[3,2-*d*] pyrimi-din-6(5*H*)-one (28a)



Pyridopyrimidine TFA salt 27 a (24.7 mg, 89 µmol, 1.00 eq), pyridopyrimidine **18c** (20.0 mg, 89 µmol, 1.00 eq), Pd₂dba₃ (3.3 mg, 4 µmol, 0.04 eq), XantPhos (6.2 mg, 11 µmol, 0.12 eq) and Cs₂CO₃ (61.1 mg, 187 µmol, 2.10 eq) were suspended in 1,4-dioxane (0.90 mL) and heated to 105 °C for 2.5 h. The greenish reaction mixture was filtered over a pad of celite which was rinsed with MeOH (5.00 mL) and all solvents were evaporated from the filtrate under reduced pressure. The crude product was purified by column chromatography on silica (CHCl₃/MeOH 12:1) to give compound 28a (20.0 mg, 66 μ mol, 74%) as highly yellow solid. R_f=0.36 (CHCl₃/MeOH 8:1). ¹H-NMR (500 MHz, DMSO-d6): δ = 12.72 (s, 1H, NHCO), 9.51 (s, 1H, CH_{arom}), 9.31 (s, 1H, CH_{arom}), 8.88 (s, 1H, CH_{arom}), 8.73 (s, 1H, NH), 8.68 (s, 1H, CH_{arom}), 8.31 (s, 1H, CH_{arom}), 7.26 (s, 1H, CH_{arom}), 2.76 (s, 3H, CH₃) ppm. ¹³C-NMR (126 MHz, DMSO-d6): $\delta =$ 159.2 (1 C, CH_{arom}), 157.9 (1 C, C_{arom}), 156.9 (1 C, C_{arom}), 155.4 (1 C, CH_{arom}), 152.7 (1 C, CH_{arom}), 146.3 (1 C, C_{arom}), 143.6 (1 C, C_{arom}), 142.9 $(1 \text{ C}, \text{ CH}_{arom})$, 140.1 (1 C, C_{arom}), 139.4 (1 C, C_{arom}), 135.9 (1 C, C_{arom}), 126.6 (1 C, C_{arom}), 123.3 (1 C, CH_{arom}), 107.6 (1 C, CH_{arom}), 21.9 (1 C, CH₃) ppm. FT-IR: neat; $\tilde{v} = 3308$ (w), 2993 (w), 2901 (w), 2837 (w), 2742 (w), 2128 (w), 1674 (m), 1619 (w), 1587 (w), 1525 (s), 1460 (w), 1416 (w), 1360 (m), 1245 (w), 1217 (w), 1196 (w), 1174 (w), 1122 (w), 1090 (w), 1023 (w), 1002 (w), 933 (w), 872 (m), 758 (w), 691 (w), 639 (m), 575 (m), 509 (w), 472 (w), 450 (w) cm⁻¹. m.p.: 253 °C decomposition (MeOH). HRMS (ESI⁺): m/z calc. for C₁₅H₁₁N₇O₁H₁ [M +H]⁺: 306.1098, found: 306.1099.

7-((6-Methyl-2-(methylthio)pyrido[3,2-*d*]pyrimidin-7-yl) amino)-2-(methylthio)-pyrido[3,2-*d*]pyrimidin-6(5*H*)-one (28 b)



Pyridopyrimidine TFA salt **27 b** (83.5 mg, 259 μ mol, 1.00 eq), pyridopyrimidine **18 g** (70.0 mg, 259 μ mol, 1.00 eq), Pd₂dba₃ (9.5 mg, 10 μ mol, 0.04 eq), XantPhos (18.0 mg, 31 μ mol, 0.12 eq) and Cs₂CO₃ (177 mg, 544 μ mol, 2.10 eq) were suspended in 1,4-dioxane (2.50 mL) and heated to 105 °C for 8.5 h. The greenish reaction mixture was filtered over a pad of celite which was rinsed with EtOAc/MeOH (10:1, 10.0 mL) and all solvents were evaporated from the filtrate under reduced pressure. The crude product was purified by column chromatography on silica (CHCl₃/MeOH 20:1) to give compound **28 b** (103 mg, 259 μ mol, 99%) as highly yellow

Eur. J. Org. Chem. **2021**, 1–20

www.eurioc.ora



solid. $R_f = 0.29$ (EtOAc). ¹H-NMR (500 MHz, DMSO-d6): $\delta = 12.59$ (s, 1H, NHCO), 9.27 (s, 1H, CH_{arom}), 8.68 (s, 1H, NH), 8.51 (s, 1H, CH_{arom}), 8.11 (s, 1H, CH_{arom}), 7.13 (s, 1H, CH_{arom}), 2.71 (s, 3H, CH_3), 2.64 (s, 3H, SCH_3), 2.50 (s, 3H, SCH_3) ppm. ¹³C-NMR (126 MHz, DMSO-d6): $\delta = 168.2$ (1 C, $C_{arom}SCH_3$), 164.1 (1 C, $C_{arom}SCH_3$), 159.3 (1 C, CH_{arom}), 156.4 (1 C, NHCO), 155.6 (1 C, C_{arom}), 147.0 (1 C, C_{arom}), 144.6 (1 C, C_{arom}), 143.6 (1 C, CH_{arom}), 121.9 (1 C, CH_{arom}), 106.8 (1 C, CH_{arom}), 2.15 (1 C, CH_3), 120.1 (1 C, SCH_3), 137.1 (1 C, SCH_3) ppm. FT-IR: neat; $\tilde{\nu} = 3264$ (w), 3144 (w), 2840 (w), 2740 (w), 2192 (w), 1679 (m), 1617 (w), 1599 (w), 1576 (w), 1536 (s), 1444 (w), 1421 (w), 1398 (w), 1371 (m), 1334 (w), 1312 (w), 1223 (w), 1179 (w), 1132 (m), 963 (w), 940 (w), 851 (w), 760 (w), 708 (w), 690 (w), 656 (w), 636 (w), 604 (w), 582 (m), 533 (w), 514 (w), 448 (w), 417 (w) cm⁻¹. m.p.: 285 °C decomposition (MeOH). HRMS (ESI⁺): m/z calc. for $C_{17}H_{15}N_7O_1S_2H_1$

tert-Butyl (6-methyl-2-(methylthio)pyrido[3,2-*d*] pyrimidin-7-yl)(2-(methylthio)-6-*oxo*-5,6-dihydropyrido[3,2-*d*] pyrimidin-7-yl)carbamate (29)



Compound 28b (100 mg, 252 µmol, 1.00 eg) and DMAP (3.1 mg, 25 μ mol, 0.10 eq) were suspended in THF (4.50 mL) cooled to 0 °C and DIPEA (90 µL, 528 µmol, 2.10 eq) was added. The solution was stirred for 5 min before Boc₂O (1 m in THF, 516 µL, 516 µmol, 2.05 eq) was added. The reaction mixture was stirred for 5.5 h while it was allowed to warm to rt. The dark orange reaction mixture was poured into saturated aqueous NH₄Cl-solution (10 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were washed with brine (20 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (n-pentane/EtOAc 2:1 to EtOAc) to give as single regioisomer Boc₂-compound (71.0 mg, 119 μ mol, 47%, 51% brsm) as white foam and Boc₁-compound **29** (55.0 mg, 111 µmol, 44%, 48% brsm) as pale yellow solid. By doing 2D-TLC it was found that Boc2-compound decomposes during column chromatography on silica to Boc1-compound 29 with the free amide-functionality. That's why Boc2-compound was later on converted into Boc₁-compound 29 by doing another column. The overall yield is 91% and 99% brsm respectively. $R_f = 0.81$ (EtOAc). ¹H-NMR (500 MHz, DMSO-d6): $\delta = 12.44$ (s, 1H, NHCO), 9.35 (s, 1H, CH_{arom}), 8.70 (s, 1H, CH_{arom}), 8.05 (s, 1H, CH_{arom}), 8.04 (s, 1H, CH_{arom}), 2.71 (s, 3H, CH₃), 2.57 (s, 3H, SCH₃), 2.53 (s, 3H, SCH₃), 1.42 (s, 9H, C(CH₃)₃) ppm. ¹³C-NMR (126 MHz, DMSO-d6): $\delta = 168.3$ (1 C, C_{arom}SCH₃), 164.2 (1 C, C_{arom}SCH₃), 160.1 (1 C, CH_{arom}), 159.7 (1 C, C_{arom}), 157.6 (1 C, C_{arom}), 151.6 (1 C, NCO₂^tBu), 146.3 (1 C, C_{arom}), 146.0 (1 C, CH_{arom}), 142.0 (1 C, C_{arom}), 141.8 (1 C, C_{arom}), 141.2 (1 C, NHCO), 135.6 (1 C, C_{arom}), 134.1 (1 C, CH_{arom}), 130.4 (1 C, CH_{arom}), 128.1 (1 C, Carom), 82.7 (1 C, C(CH₃)₃), 27.6 (3 C, C(CH₃)₃), 21.8 (1 C, CH₃), 14.0 (1 C, SCH₃), 13.8 (1 C, SCH₃) ppm. FT-IR: neat; $\tilde{v} = 2975$ (w), 2925 (w), 2849 (w), 2544 (w), 2219 (w), 2188 (w), 2167 (w), 2102 (w), 2036 (w), 2003 (w), 1967 (w), 1709 (s), 1659 (s), 1606 (w), 1569 (m), 1548 (w), 1474 (w), 1446 (w), 1386 (s), 1310 (m), 1261 (w), 1241 (w), 1190 (w), 1144 (w), 1125 (s), 1043 (w), 1021 (w), 958 (w), 935 (w), 911 (w), 866 (w), 823 (w), 804 (w), 766 (w), 731 (w), 708 (w), 672 (w), 648 (w), 605 (m), 579 (w), 561 (w), 542 (w), 474 (w), 447 (w) cm⁻¹. m.p.: 305 °C decomposition (EtOAc). HRMS (ESI⁺): m/z calc. for C₂₂H₂₃N₇O₃S₂Na₁ [M+Na]⁺: 520.1196, found: 520.1205.

7-((*tert*-Butoxycarbonyl)(6-methyl-2-(methylthio)pyrido[3,2-*d*] pyrimidin-7-yl)amino)-2-(methylthio)pyrido[3,2-*d*] pyrimidin-6-yl 4-methylbenzenesulfonate (30 a)



Compound 29 (100 mg, 201 µmol, 1.00 eq), TosCl (46.0 mg, 241 µmol, 1.20 eq) and DMAP (2.5 mg, 20 µmol, 0.10 eq) were suspended in THF (3.50 mL) cooled to 0 $^\circ\text{C}$ and DIPEA (41.0 $\mu\text{L},$ 241 µmol, 1.20 eq) was added. The solution was stirred for 6 h before it was poured into saturated aqueous NH₄Cl-solution (10 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were washed with brine (20 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (n-pentane/EtOAc 2:1) to give as single regioisomer compound 30a (124 mg, 190 µmol, 95%, 99% brsm) as pale yellow foam. R_f=0.39 (npentane/EtOAc 2:1). ¹H-NMR (500 MHz, CDCl₃): δ = 9.38 (s, 1H, CH_{arom}), 9.08 (s, 1H, CH_{arom}), 7.95 (s, 1H, CH_{arom}), 7.93 (d, J=8.3 Hz, 2H, $2 \times CH_{Tos}$), 7.85 (s, 1H, CH_{arom}), 7.31 (d, J = 8.3 Hz, 2H, $2 \times CH_{Tos}$), 2.78 (s, 3H, CH₃), 2.63 (s, 3H, SCH₃), 2.61 (s, 3H, SCH₃), 2.45 (s, 3H, Tos-CH₃) ppm. ¹³C-NMR (126 MHz, CDCl₃): $\delta = 171.1$ (1 C, C_{arom}SCH₃), 170.3 (1 C, C_{arom}SCH₃), 159.9 (1 C, CH_{arom}), 159.1 (1 C, CH_{arom}), 159.0 (1 C, C_{arom}), 151.6 (1 C, NCO₂^tBu), 151.0 (1 C, C_{arom}), 146.6 (1 C, C_{arom}), 146.4 (1 C, C_{arom}) 146.4 (1 C, C_{Tos}), 141.7 (1 C, C_{arom}), 136.0 (1 C, C_{arom}), 135.1 (1 C, CH_{arom}), 134.2 (1 C, C_{arom}), 133.5 (1 C, C_{arom}), 133.5 (1 C, C_{Tos}), 132.7 (1 C, CH_{arom}), 129.8 (2 C, 2× CH_{Tos}), 129.4 (2 C, 2× CH_{Tos}), 84.9 (1 C, C(CH₃)₃), 28.1 (3 C, C(CH₃)₃), 21.9 (1 C, Tos-CH₃), 21.9 (1 C, CH₃), 14.8 (1 C, SCH₃), 14.7 (1 C, SCH₃) ppm. FT-IR: neat; $\tilde{v} = 2978$ (w), 2927 (w), 1723 (m), 1601 (w), 1567 (m), 1546 (w), 1433 (w), 1387 (m), 1294 (m), 1255 (w), 1152 (w), 1125 (s), 1087 (w), 1040 (w), 1016 (w), 948 (w), 904 (w), 868 (w), 811 (w), 788 (w), 745 (m), 711 (w), 684 (w), 663 (m), 611 (w), 575 (w), 546 (m), 527 (w), 450 (w) cm⁻¹. m.p.: 126 °C (EtOAc). HRMS (ESI⁺): m/z calc. for $C_{29}H_{29}N_7O_5S_3Na_1$ [M + Na]⁺ : 674.1285, found: 674.1279.

7-((*tert*-Butoxycarbonyl)(6-methyl-2-(methylthio)pyrido[3,2-*d*] pyrimidin-7-yl)amino)-2-(methylthio)pyrido[3,2-*d*] pyrimidin-6-yl 2-nitrobenzenesulfonate (30 b)



Compound **29** (13.5 mg, 27 µmol, 1.00 eq), 2-NosCl (6.8 mg, 27 µmol, 1.10 eq) and DMAP (0.3 mg, 3 µmol, 0.10 eq) were suspended in THF (0.50 mL) cooled to 0°C and DIPEA (5.0 µL, 30 µmol, 1.10 eq) was added. The solution was stirred for 2.5 h before it was poured into saturated aqueous NH₄Cl-solution (5 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (*n*-pentane/EtOAc 2:1 to 1:1) to give as single regioisomer compound **30b** (14.0 mg, 21 µmol, 76%) as pale yellow foam. R_f =0.47 (*n*-pentane/EtOAc 1:1). ¹H-NMR (500 MHz, CDCl₃): δ =9.34 (s, 1H, CH_{arom}), 8.91 (s, 1H, CH_{arom}), 8.43 (d, *J*=7.52 Hz, 1H, CH_{Nos}), 8.05 (s, 1H, CH_{arom}), 7.94 (s, 1H, CH_{arom}), 7.89–7.83 (m, 3H, 3×CH_{Nos}), 2.82 (s, 3H, CH₃), 2.61 (s, 3H, SCH₃), 1.52 (s, 9H, C(CH₃)₃) ppm. ¹³C-NMR (126

www.eurjoc.org



MHz, CDCl₃): δ = 171.5 (1 C, C_{arom}SCH₃), 170.0 (1 C, C_{arom}SCH₃), 160.2 (1 C, CH_{arom}), 159.2 (1 C, C_{arom}), 158.8 (1 C, CH_{arom}), 151.6 (1 C, NCO₂^tBu), 150.8 (1 C, C_{arom}), 148.8 (1 C, C_{Nos}), 146.6 (1 C, C_{arom}), 146.6 (1 C, C_{arom}), 141.4 (1 C, C_{arom}), 136.5 (1 C, C_{arom}), 135.8 (1 C, CH_{Nos}), 135.6 (1 C, CH_{arom}), 133.3 (1 C, CH_{Nos}), 133.2 (1 C, C_{arom}), 132.7 (1 C, CH_{arom}), 132.2 (1 C, CH_{Nos}), 130.9 (1 C, C_{arom}), 130.0 (1 C, C_{Nos}), 125.1 (1 C, CH_{Nos}), 85.2 (1 C, C(CH₃)₃), 28.1 (3 C, C(CH₃)₃), 22.0 (1 C, CH₃), 148.8 (1 C, SCH₃), 14.7 (1 C, SCH₃) ppm. FT-IR: neat; $\tilde{\nu}$ = 2977 (w), 2927 (w), 1724 (m), 1604 (w), 1568 (w), 1543 (s), 1435 (w), 1394 (m), 1367 (w), 1330 (w), 1296 (m), 1255 (w), 1191 (w), 1151 (w), 1123 (s), 1041 (w), 1017 (w), 948 (w), 905 (w), 869 (w), 796 (m), 760 (w), 733 (m), 652 (w), 609 (w), 582 (m), 528 (w), 448 (w) cm⁻¹. m.p.: 110°C (EtOAc). HRMS (ESI⁺): *m/z* calc. for C₂₈H₂₆N₈O₇S₃Na₁ [M+Na]⁺: 705.0979, found: 705.0973.

7-((*tert*-Butoxycarbonyl)(6-methyl-2-(methylthio)pyrido[3,2-*d*] pyrimidin-7-yl)amino)-2-(methylthio)pyrido[3,2-*d*] pyrimidin-6-yl trifluoromethanesulfonate (30 c)



Compound 29 (33.0 mg, 66 µmol, 1.00 eq) and DMAP (0.8 mg, 7 µmol, 0.10 eq) were suspended in THF (1.00 mL) cooled to 0°C and DIPEA (16.0 µL, 93 µmol, 1.40 eq) was added. After 5 min TfCl (8.0 µL, 80 µmol, 1.20 eq) was added dropwise. The solution was stirred for 16 h during which it was allowed to warm up to rt before it was poured into saturated aqueous NaHCO₃-solution (5 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica (n-pentane/EtOAc 2:1) to give compound 30c (28.0 mg, 45 µmol, 68%, 89% brsm) as pale yellow foam. $R_f = 0.77$ (*n*-pentane/EtOAc 1:1). ¹H-NMR (500 MHz, CDCl₃): $\delta = 9.34$ (d, J = 0.8 Hz, 1H, CH_{arom}), 9.24 (d, J = 0.8 Hz, 1H, CH_{arom}), 7.94 (s, 1H, CH_{arom}), 7.88 (d, J = 0.7 Hz, 1H, CH_{arom}), 2.76 (s, 3H, CH₃), 2.64 (s, 3H, SCH₃), 2.61 (s, 3H, SCH₃), 1.50 (s, 9H, C(CH₃)₃) ppm. $^{\rm 13}\text{C-NMR}$ (126 MHz, CDCl_3): $\delta\!=\!$ 172.6 (1 C, $C_{\rm arom}\text{SCH}_3$), 170.6 (1 C, $C_{arom}SCH_3$), 160.3 (1 C, CH_{arom}), 159.6 (1 C, CH_{arom}), 158.2 (1 C, C_{arom}), 151.4 (1 C, NCO₂^tBu), 149.1 (1 C, C_{arom}), 147.1 (1 C, C_{arom}), 146.5 $(1 \text{ C}, C_{\text{arom}})$, 141.0 $(1 \text{ C}, C_{\text{arom}})$, 136.7 $(1 \text{ C}, C_{\text{arom}})$, 135.3 $(1 \text{ C}, CH_{\text{arom}})$, 134.4 (1 C, C_{arom}), 133.3 (1 C, CH_{arom}), 133.3 (1 C, C_{arom}), 118.7 (q, J= 321.2 Hz, 1 C, CF₃), 85.5 (1 C, C(CH₃)₃), 28.0 (3 C, C(CH₃)₃), 22.0 (1 C, CH₃), 14.8 (1 C, SCH₃), 14.8 (1 C, SCH₃) ppm. ¹⁹F-NMR (283 MHz, CDCl₃): $\delta = -72.6$ (s, 3F, CF₃) ppm. FT-IR: neat; $\tilde{v} = 2979$ (w), 2928 (w), 1727 (m), 1603 (w), 1567 (w), 1545 (w), 1427 (m), 1405 (w), 1371 (w), 1294 (w), 1212 (m), 1124 (s), 1040 (w), 1015 (w), 946 (w), 901 (w), 874 (m), 808 (m), 757 (w), 713 (w), 640 (w), 598 (m), 504 (w), 451 (w) cm⁻¹. m.p.: 107 °C (EtOAc). HRMS (ESI⁺): m/z calc. for $C_{23}H_{22}F_{3}N_{7}O_{5}S_{3}H_{1}$ [M + H]⁺: 630.0869, found: 630.0869.

Deposition Numbers 2081819 (for **18**e), 2081820 (for **17**b), 2081821 (for **19**d), 2081822 (for **28**a), 2081823 (for **19**j), and 2081824 (for **17**d) contain the supplementary crystallographic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures service www.ccdc.cam.ac.uk/ structures.

Acknowledgements

We acknowledge support by the German Science Foundation (Grant SFB 1083, TP A8). Open access funding enabled and organized by Projekt DEAL.

Conflict of Interest

The authors declare no conflict of interest.

Keywords: HWE-reaction • Nitrogen heterocycles Photoisomerization • Pyridopyrimidine • Synthetic methods

- [1] F. Buron, J. Y. Merour, M. Akssira, G. Guillaumet, S. Routier, *Eur. J. Med. Chem.* 2015, 95, 76–95.
- [2] R. L. Mackman, M. Mish, G. Chin, J. K. Perry, T. Appleby, Y. Aktoudianakis, S. Metobo, P. Pyun, C. Niu, S. Daffis, H. Yu, J. Zheng, A. G. Villasenor, J. Zablocki, J. Chamberlain, H. Jin, G. Lee, K. Suekawa-Pirrone, R. Santos, W. E. Delaney, S. P. Fletcher, J. Med. Chem. 2020, 63, 10188–10203.
- [3] M. N. Kim, S. M. Lee, J. S. Kim, S. G. Hwang, *Cancer Chemother*. *Pharmacol.* **2019**, *84*, 809–817.
- [4] D. Nguyen, C. Lemos, L. Wortmann, K. Eis, S. J. Holton, U. Boemer, D. Moosmayer, U. Eberspaecher, J. Weiske, C. Lechner, S. Prechtl, D. Suelzle, F. Siegel, F. Prinz, R. Lesche, B. Nicke, K. Nowak-Reppel, H. Himmel, D. Mumberg, F. v. Nussbaum, C. F. Nising, M. Bauser, A. Haegebarth, J. Med. Chem. 2019, 62, 928–940.
- [5] R. A. Allen, D. C. Brookings, M. J. Powell, J. Delgado, L. K. Shuttleworth, M. Merriman, I. J. Fahy, R. Tewari, J. P. Silva, L. J. Healy, G. C. G. Davies, B. Twomey, R. M. Cutler, A. Kotian, A. Crosby, G. McCluskey, G. F. Watt, A. Payne, J. Pharmacol. Exp. Ther. 2017, 361, 429–440.
- [6] D. M. Goldstein, M. Soth, T. Gabriel, N. Dewdney, A. Kuglstatter, H. Arzeno, J. Chen, W. Bingenheimer, S. A. Dalrymple, J. Dunn, R. Farrell, S. Frauchinger, J. La Fargue, M. Ghate, B. Graves, R. J. Hill, F. Li, R. Litman, B. Loe, J. McIntosh, D. McWeeney, E. Papp, J. Park, H. F. Reese, R. T. Roberts, D. Rotstein, B. S. Pablo, K. Sarma, M. Stahl, M. L. Sung, R. T. Suttman, E. B. Sjogren, Y. Tan, A. Trejo, M. Welch, P. Weller, B. R. Wong, H. Zecic, J. Med. Chem. 2011, 54, 2255–2265.
- [7] T. Wixe, J. J. Christensen, S. Lidin, P. Fristrup, K. Wärnmark, Org. Biomol. Chem. 2014, 12, 8930–8941.
- [8] Y. Yamamoto in Science of Synthesis, Hetarenes and Related Ring Systems: Six-Membered Hetarenes with Two Identical Heteroatoms, Vol. 16 (Eds.: D. Bellus, E. N. Jacobsen, S. V. Ley, R. Noyori, M. Regitz, P. J. Reider, E. Schaumann, I. Shinkai, E. J. Thomas, B. M. Trost), Georg Thieme Verlag, Stuttgart, New York, 2004, pp. 1155–1225.
- [9] a) C. Cocaud, A. Maujoin, R. B. Zheng, T. L. Lowary, N. Rodrigues, N. Percina, A. Chartier, F. Buron, S. Routier, C. Nicolas, O. R. Martin, *Eur. J. Org. Chem.* **2017**, *41*, 6192–6201; b) T. Mizuno, N. Okamoto, T. Ito, T. Miyata, *Tetrahedron Lett.* **2000**, *41*, 1051.
- [10] a) A. Tikad, O. Dehbi, M. Akssira, M. Aadil, S. Massip, J. M. Leger, C. Jarry, G. Guillaumet, S. Routier, Synthesis 2013, 491–500; b) G. Bouscary-Desforges, A. Bombrum, J. K. Augustine, G. Bernardinelly, A. Quattropani, J. Org. Chem. 2012, 77, 4586–4595; c) A. Tikad, M. Akssira, S. Massip, J. M. Leger, C. Jarry, G. Guillaumet, S. Routier, Eur. J. Org. Chem. 2012, 4523–4532; d) A. Tikad, S. Routier, M. Akssira, J. M. Leger, C. Jarry, G. Guillaumet, S. Routier, M. Akssira, J. M. Leger, C. Jarry, G. Guillaumet, Org. Lett. 2007, 9, 4673–4676; f) A. Tikad, S. Routier, M. Akssira, J. M. Leger, C. Jarry, G. Guillaumet, Org. Lett. 2007, 9, 4673–4676; f) A. Tikad, S. Routier, M. Akssira, J. M. Leger, N. Akssira, J. M. Leger, P. Jarry, G. Guillaumet, Synlett 2006, 1938–1942.
- [11] J. I. Graw, W. T. Colwell, V. H. Brown, M. Sato, R. L. Kisliuk, Y. Gaumont, J. Thorndike, F. M. Sirotnak, *J. Med. Chem.* **1988**, *31*, 150–153.
- [12] a) M. Winkler, K. N. Houk, J. Am. Chem. Soc. 2007, 129, 1805–1815; b) J.
 Schwaben, N. Münster, M. Klues, T. Breuer, P. Hofmann, K. Harms, G.
 Witte, U. Koert, Chem. Eur. J. 2015, 21, 13758–13771; c) A. L. Appleton,
 S. M. Brombosz, S. Barlow, J. S. Sears, J. L. Bredas, S. R. Marder, U. H.
 Bunz, Nat. Commun. 2010, 91, 1–6; d) Z. Zhang, O. Zhang, Mater. Chem.
 Front. 2020, 4, 3419–3432.
- [13] F. Himmelsbach, T. v. Rüden, G. Dahmann, T. Metz, WO1996007657 A1, 1996.

18



- [14] T. Wixe, C.-J. Wallentin, M. T. Johnson, P. Fristrup, S. Lidin, K. Wärnmark, Chem. Eur. J. 2013, 19, 14963–14969.
- [15] T. H. Graham, W. Liu, D.-M. Shen, Org. Lett. 2011, 13, 6232–6235.
- [16] C. E. McKenna, L. A. Khawli, J. Org. Chem. 1986, 51, 5467–5471.
- [17] T. Horaguchi, N. Hosokawa, K. Tanemura, T. Suzuki, J. Heterocycl. Chem. 2002, 39, 61–67.
- [18] K. Tago, H. Kogen, Org. Lett. 2000, 2, 1975–1978.
- [19] a) M. Kitamura, M. Tokunaga, R. Noyori, J. Am. Chem. Soc. 1995, 117, 2931–2932; b) J. P. Haelters, B. Corbel, G. Sturtz, Phosphorus Sulfur Relat. Elem. 1988, 37, 65–85.
- [20] a) J. Coste, E. Frerot, P. Jouin, B. Castro, *Tetrahedron Lett.* **1991**, *32*, 1967–1970; b) F.-A. Kang, J. Kodah, Q. Guan, X. Li, W. V. Murray, J. Org. Chem. **2005**, *70*, 1957–1960.
- [21] Sigma-Aldrich, Aldrich Technical Information Bulletin 2007, AL-180.

Manuscript received: May 15, 2021 Revised manuscript received: July 8, 2021 Accepted manuscript online: July 16, 2021

FULL PAPERS



Substituted pyrido[3,2-d]pyrimidines are accessible by a reaction sequence consisting of HWE-reaction, a Z/E-photoisomerization, and ring closure of the pyridine ring. Bis-pyridopyrimidines can be obtained from 7-aminopyrido[3,2-*d*]pyrimidines. Dr. P. E. Hofmann, J. Meinecke, Dr. K. Harms, Prof. Dr. U. Koert*

1 – 20

Synthesis and Functionalization of C6/C7 Substituted Pyrido[3,2-d] pyrimidines